## Phase II, Randomized Trial Comparing Bevacizumab Pl With FU/LV Alone in Patients With Metastatic Colorecta

Journal of Clinical Oncology 21, 60-65 DOI: 10.1200/jco.2003.10.066

**Citation Report** 

#	Article	IF	CITATIONS
1	General discussion II. , 0, , 169-172.		0
2	Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. International Journal of Oncology, 1992, 34, 401.	3.3	6
3	Endothelial factors. , 2001, , 50-77.		0
4	Immunological factors and placentation: implications for pre-eclampsia. , 2001, , 103-120.		0
5	Vascular Endothelial Growth Factors. , 2002, , 883-XXXV.		1
6	Drug Development in Pancreatic Cancer: Finally, Biology Begets Therapy. International Journal of Gastrointestinal Cancer, 2003, 32, 91-106.	0.4	0
7	New targeted therapies in gastrointestinal cancers. Current Treatment Options in Oncology, 2003, 4, 393-403.	3.0	20
8	Ausblicke in die n�here und weitere Zukunft der Tumortherapie. Onkologe, 2003, 9, 553-557.	0.7	0
9	Inhibition der Signaltransduktion als therapeutisches Prinzip. Onkologe, 2003, 9, 1088-1101.	0.7	0
10	Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. Seminars in Radiation Oncology, 2003, 13, 441-453.	2.2	11
11	Current status of oxaliplatin in colorectal cancer. Seminars in Oncology, 2003, 30, 78-87.	2.2	24
12	Seeking the solution to the problem of metastatic renal carcinoma. Cancer, 2003, 97, 2941-2944.	4.1	4
13	Colorectal cancer chemotherapy. Alimentary Pharmacology and Therapeutics, 2003, 18, 683-692.	3.7	57
14	Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia, 2003, 17, 1961-1966.	7.2	74
15	The biology of VEGF and its receptors. Nature Medicine, 2003, 9, 669-676.	30.7	8,501
16	Validation of the Role of Angiogenesis as a Chemotherapeutic Target. Clinical Colorectal Cancer, 2003, 3, 74-75.	2.3	0
17	Development of New Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 154-164.	2.3	5
18	The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 153-159.	2.1	19

#	Article	IF	CITATIONS
19	Adding a Humanized Antibody to Vascular Endothelial Growth Factor (Bevacizumab, Avastinâ,,¢) to Chemotherapy Improves Survival in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 85-88.	2.3	19
20	Current Studies with PTK787, an Oral Inhibitor of Vascular Endothelial Growth Factor in Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 147-149.	2.3	11
21	Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria. Journal of Biological Chemistry, 2003, 278, 12605-12608.	3.4	472
22	The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opinion on Biological Therapy, 2003, 3, 1105-1120.	3.1	103
23	Antibodies as therapeutic agents: vive la renaissance!. Expert Opinion on Biological Therapy, 2003, 3, 1133-1152.	3.1	73
24	The therapeutic potential of novel antiangiogenic therapies. Expert Opinion on Investigational Drugs, 2003, 12, 923-932.	4.1	22
25	Recent developments in the pharmacological treatment of advanced pancreatic cancer. Expert Opinion on Investigational Drugs, 2003, 12, 983-992.	4.1	7
26	Fish Oil Supplementation in Patients With Advanced Cancer. Journal of Clinical Oncology, 2003, 21, 3545-3545.	1.6	3
27	Antiangiogenic Therapy: More Promise and, Yet Again, More Questions. Journal of Clinical Oncology, 2003, 21, 3897-3899.	1.6	18
28	Angiogenesis: Basic Mechanisms and Clinical Applications. Seminars in Cardiothoracic and Vascular Anesthesia, 2003, 7, 253-280.	1.0	3
31	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. Expert Opinion on Investigational Drugs, 2003, 12, 577-592.	4.1	1
32	VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy, 2003, 3, 263-276.	3.1	159
33	Can Colorectal Cancer Patients With Thymidylate Synthase–Overexpressing Liver Metastases Have an Overall Survival Advantage With Hepatic Arterial Infusion Alone?. Journal of Clinical Oncology, 2003, 21, 3543-3544.	1.6	2
34	Treatment of Metastatic Colorectal Cancer With Monoclonal Antibody to Vascular Endothelial Growth Factor: Does the Metastatic Site Make the Difference?. Journal of Clinical Oncology, 2003, 21, 3542-3543.	1.6	13
35	Recent advances in the pharmacological treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2003, 12, 423-434.	4.1	8
36	Bevacizumab, Bleeding, Thrombosis, and Warfarin. Journal of Clinical Oncology, 2003, 21, 3542-3542.	1.6	155
37	Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thrombosis and Haemostasis, 2003, 90, 734-737.	3.4	44
38	Metastatic Colorectal Cancer: Systemic Treatment in the New Millennium. Cancer Control, 2003, 10, 224-238.	1.8	34

	CITATION	REPORT	
#	Article	IF	Citations
40	Emerging drugs in colorectal cancer. Expert Opinion on Emerging Drugs, 2003, 8, 193-202.	2.4	2
41	Thromboembolism associated with new anti-cancer treatment strategies in combination with conventional chemotherapy: new drugs, old risks?. Thrombosis and Haemostasis, 2003, 90, 567-569.	3.4	10
42	Nuove combinazioni di irinotecan con i farmaci "molecular targeted―nel trattamento del carcinoma del colon-retto. Tumori, 2003, 89, 1-11.	1.1	0
43	Antiangiogenic Tumor Therapy. BioTechniques, 2003, 34, 1048-1063.	1.8	12
44	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	1.8	24
45	Overview of Bevacizumab: A New Cancer Therapeutic Strategy Targeting Vascular Endothelial Growth Factor. American Journal of Health-System Pharmacy, 2004, 61, S21-S26.	1.0	58
46	ASCO Annual Meeting 2004, New Orleans Angiogenesi Tumorale ed Inibizione di VEGF: Implicazioni Cliniche. Tumori, 2004, 90, 1-12.	1.1	0
47	Angiogenesis: A Target for Cancer Therapy. Current Pharmaceutical Design, 2004, 10, 11-26.	1.9	72
49	Resistance to Anti-VEGF Agents. Current Pharmaceutical Design, 2004, 10, 51-64.	1.9	20
50	Clinical Development Issues. , 2004, , 287-306.		1
51	Prognostic and Predictive Markers in Cancer. Disease Markers, 2004, 20, 35-43.	1.3	44
52	Colorectal Polyposis and Immune-Based Therapies. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 239-249.	1.7	8
53	Antiangiogenic Therapy in Hematologic Malignancies. Current Pharmaceutical Design, 2004, 10, 1221-1234.	1.9	31
54	Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Annals of Oncology, 2004, 15, 1261-1266.	1.2	69
55	Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs, 2004, 13, 577-607.	4.1	6
56	Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2004, 13, 609-629.	4.1	2
57	Colon cancer angiogenesis and antiangiogenic therapy. Expert Opinion on Investigational Drugs, 2004, 13, 631-641.	4.1	16
58	Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Expert Review of Anticancer Therapy, 2004, 4, 129-140.	2.4	14

#	Article	IF	CITATIONS
59	Targeted therapy in advanced colon cancer: the role of new therapies. Annals of Oncology, 2004, 15, iv55-iv62.	1.2	27
60	Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 947-955.	2.4	4
61	An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model. Clinical Cancer Research, 2004, 10, 1430-1438.	7.0	68
62	Blockage of 2-Deoxy- <scp>d</scp> -Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil Therapy. Clinical Cancer Research, 2004, 10, 1843-1852.	7.0	60
63	Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab. Oncologist, 2004, 9, 11-18.	3.7	93
64	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. Clinical Cancer Research, 2004, 10, 5137-5144.	7.0	102
65	Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias. Clinical Cancer Research, 2004, 10, 3577-3585.	7.0	183
66	Which drug combination for colorectal cancer?. Expert Opinion on Pharmacotherapy, 2004, 5, 2621-2624.	1.8	1
67	Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 1177-1179.	1.6	47
68	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2004, 9, 91-104.	2.4	3
69	The Past Decade of Experience With Isolated Hepatic Perfusion. Oncologist, 2004, 9, 653-664.	3.7	54
70	The Role of Vascular Endothelial Growth Factor in the Kidney in Health and Disease. Nephron Physiology, 2004, 98, p73-p79.	1.2	28
71	A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria. Nephron Physiology, 2004, 96, p26-p36.	1.2	16
73	Maximizing the Potential of Bevacizumab in Cancer Treatment. Oncologist, 2004, 9, 36-42.	3.7	78
74	Modulating Angiogenesis. JAMA - Journal of the American Medical Association, 2004, 292, 972.	7.4	88
75	Prospective Clinical Trials Using a Pharmacogenetic/Pharmacogenomic Approach. Journal of Chemotherapy, 2004, 16, 25-30.	1.5	15
76	cDNA microarray analysis of endothelial cells in response to green tea reveals a suppressive phenotype. International Journal of Oncology, 2004, 25, 193.	3.3	6
78	Expression Pattern of the Novel Gene EG-1 in Cancer. Clinical Cancer Research, 2004, 10, 3504-3508.	7.0	24

#	Article	IF	CITATIONS
79	Vascular biology support for the use of bevacizumab in colorectal cancer. Expert Opinion on Investigational Drugs, 2004, 13, 703-705.	4.1	1
80	A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models. Molecular Pharmacology, 2004, 66, 635-647.	2.3	44
81	Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development. Clinical Cancer Research, 2004, 10, 3885-3896.	7.0	156
82	Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC. Cancer Research, 2004, 64, 7420-7425.	0.9	47
83	Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECIST. Journal of Clinical Oncology, 2004, 22, 4442-4445.	1.6	218
84	New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers. Oncologist, 2004, 9, 282-294.	3.7	77
85	Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. British Journal of Cancer, 2004, 90, 1429-1436.	6.4	184
86	Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 2184-2191.	1.6	1,917
87	Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy. Cancer Investigation, 2004, 22, 762-773.	1.3	16
89	Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 627-637.	2.4	4
90	c-Myc as a therapeutic target in cancer. Expert Review of Anticancer Therapy, 2004, 4, 289-302.	2.4	86
91	Targeting protein kinases in cancer therapy: a success?. Expert Review of Anticancer Therapy, 2004, 4, 1113-1124.	2.4	44
92	Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. Journal of Clinical Oncology, 2004, 22, 4717-4724.	1.6	190
93	Developments in treatment of primary irresectable rectal cancer. Colorectal Disease, 2004, 6, 406-417.	1.4	3
94	Evidence-based update of chemotherapy options for metastatic colorectal cancer. ANZ Journal of Surgery, 2004, 74, 781-787.	0.7	8
95	Molecular regulation of the VEGF family – inducers of angiogenesis and lymphangiogenesis. Apmis, 2004, 112, 463-480.	2.0	139
96	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery, 2004, 3, 391-400.	46.4	2,211
97	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene, 2004, 23, 4624-4635.	5.9	70

#	Article	IF	CITATIONS
98	Identification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen. Oncogene, 2004, 23, 8158-8170.	5.9	15
99	Angiogenesis inhibitors in clinical development; where are we now and where are we going?. British Journal of Cancer, 2004, 90, 1-7.	6.4	185
100	Autocrine signaling in carcinoma: VEGF and the α6β4 integrin. Seminars in Cancer Biology, 2004, 14, 115-122.	9.6	67
102	Antiangiogenic drugs and current strategies for the treatment of lung cancer. Seminars in Oncology, 2004, 31, 54-60.	2.2	28
103	Angiogenesis inhibitors in the treatment of colorectal cancer. Seminars in Oncology, 2004, 31, 10-16.	2.2	52
104	Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology, 2004, 31, 17-21.	2.2	38
105	Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell, 2004, 6, 507-516.	16.8	689
106	Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. American Journal of Obstetrics and Gynecology, 2004, 190, 1541-1547.	1.3	347
107	Pilot Study Using a Humanized CC49 Monoclonal Antibody (HuCC49°CH2) to Localize Recurrent Colorectal Carcinoma. Annals of Surgical Oncology, 2004, 11, 197-202.	1.5	28
108	Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies. Annals of Pharmacotherapy, 2004, 38, 1258-1264.	1.9	114
109	Vascular endothelial growth factor in colorectal cancer. International Journal of Colorectal Disease, 2004, 19, 510-517.	2.2	63
111	Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Techniques in Coloproctology, 2004, 8, s50-s52.	1.8	27
112	Medical treatment of advanced colorectal carcinoma. Clinical and Translational Oncology, 2004, 6, 245-257.	2.4	0
114	Integration of novel agents in the treatment of colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S32-9.	2.3	29
115	Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S57-64.	2.3	17
116	Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Current Treatment Options in Gastroenterology, 2004, 7, 343-354.	0.8	9
117	New systemic frontline treatment for metastatic colorectal carcinoma. Cancer, 2004, 100, 1558-1577.	4.1	68
118	Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer, 2004, 101,	4.1	110

#	Article	IF	CITATIONS
119	The clinical pharmacology of therapeutic monoclonal antibodies. Drug Development Research, 2004, 61, 108-120.	2.9	92
120	Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?. International Journal of Radiation Oncology Biology Physics, 2004, 58, 361-368.	0.8	12
121	A novel antiangiogenesis therapy using an integrin antagonist or anti–Flk-1 antibody coated 90Y-labeled nanoparticles. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1215-1227.	0.8	155
122	VEGF and myeloid leukemias. Leukemia Research, 2004, 28, 675-677.	0.8	17
123	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 17-27.	2.3	123
124	Using antibodies in tumour immunotherapy. Expert Opinion on Biological Therapy, 2004, 4, 1265-1284.	3.1	9
126	Antiangiogenic therapy for primary and metastatic brain tumors. Hematology/Oncology Clinics of North America, 2004, 18, 1161-1181.	2.2	20
127	Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematology/Oncology Clinics of North America, 2004, 18, 1087-1119.	2.2	5
128	Bevacizumab Improves the Efficacy of 5-Fluorouracil/Leucovorin in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 89-91.	2.3	4
129	Irinotecan in combination with new agents. European Journal of Cancer, Supplement, 2004, 2, 14-20.	2.2	5
130	Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. New England Journal of Medicine, 2004, 350, 2335-2342.	27.0	9,850
131	Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Reviews, 2004, 25, 581-611.	20.1	3,152
132	Targeting angiogenesis in cancer: clinical development of bevacizumab. Nature Clinical Practice Oncology, 2004, 1, 39-43.	4.3	85
133	New Aspects in the Pathophysiology of Preeclampsia. Journal of the American Society of Nephrology: JASN, 2004, 15, 2440-2448.	6.1	161
134	First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer. Drugs, 2004, 64, 27-44.	10.9	21
135	Current Approaches to First-Line Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S9-S15.	2.3	7
136	An Overview of Adjuvant Systemic Chemotherapy for Colon Cancer. Clinical Colorectal Cancer, 2004, 4, S22-S28.	2.3	38
137	Preclinical Data Targeting Vascular Endothelial Growth Factor in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S55-S61.	2.3	11

#	Article	IF	CITATIONS
138	Integrating the Anti–VEGF-A Humanized Monoclonal Antibody Bevacizumab with Chemotherapy in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S62-S68.	2.3	131
139	Can Inhibition of Angiogenic Pathways Increase the Efficacy of Intravenous 5-Fluorouracil–Based Regimens?. Clinical Colorectal Cancer, 2004, 4, S69-S73.	2.3	8
140	Combining Anti-VEGF Approaches with Oxaliplatin in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S74-S80.	2.3	11
141	Future Directions with Angiogenesis Inhibitors in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S86-S93.	2.3	3
143	Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine, 2004, 350, 672-683.	27.0	3,158
146	Two Steps Forward in the Treatment of Colorectal Cancer. New England Journal of Medicine, 2004, 350, 2406-2408.	27.0	99
147	Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treatment Reviews, 2004, 30, 495-513.	7.7	44
148	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates, 2004, 7, 289-300.	14.4	82
149	Monoclonal antibodies in the treatment of colorectal cancer. European Journal of Cancer, 2004, 40, 1292-1301.	2.8	74
150	Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer. Molecular Imaging and Biology, 2004, 6, 208-213.	2.6	11
151	Antiangiogenic therapy for the treatment of pediatric solid malignancies. Seminars in Pediatric Surgery, 2004, 13, 53-60.	1.1	11
153	Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Current Opinion in Oncology, 2004, 16, 385-390.	2.4	27
154	Developments in Oncology—2004. Journal of Pharmacy Practice and Research, 2004, 34, 236-238.	0.8	0
155	The role of VEGF-A in glomerular development and function. Current Opinion in Nephrology and Hypertension, 2004, 13, 9-15.	2.0	152
156	Systemic or Regional Chemotherapy for Liver Metastases from Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2004, 10, 271-279.	2.0	3
157	Stellenwert der intensivierten Chemotherapie und der neuen Substanzen in der adjuvanten und palliativen Situation beim kolorektalen Karzinom. Visceral Medicine, 2005, 21, 145-150.	1.3	0
158	Update on angiogenesis inhibitors. Current Opinion in Oncology, 2005, 17, 578-583.	2.4	70
159	Circulating Angiogenic Factors in Preeclampsia. Clinical Obstetrics and Gynecology, 2005, 48, 372-386.	1.1	131

_			_
C 17		ON	
	AL	UN	REPORT

#	Article	IF	CITATIONS
160	A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Molecular Cancer Therapeutics, 2005, 4, 948-955.	4.1	79
161	Quantitative Colorectal Cancer Perfusion Measurement Using Dynamic Contrast-Enhanced Multidetector-Row Computed Tomography. Journal of Computer Assisted Tomography, 2005, 29, 59-63.	0.9	65
163	Future therapies for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 515-521.	1.6	9
164	The Biology of Metastases in Pediatric Sarcomas. Cancer Journal (Sudbury, Mass ), 2005, 11, 306-313.	2.0	39
165	Tailored Therapy of Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2005, 11, 175-188.	2.0	3
166	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105, 986-993.	1.4	481
167	Vascular endothelial growth factor promotes sensitivity to ultraviolet B–induced cutaneous photodamage. Blood, 2005, 105, 2392-2399.	1.4	62
168	Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood, 2005, 105, 1992-1999.	1.4	109
169	Direct In Vitro Selection of a $2\hat{a}\in^2$ -O-Methyl Aptamer to VEGF. Chemistry and Biology, 2005, 12, 25-33.	6.0	306
170	Current Issues in Wilms Tumor Management. Current Problems in Cancer, 2005, 29, 223-260.	2.0	38
171	Systemic Therapy for Colorectal Cancer. New England Journal of Medicine, 2005, 352, 476-487.	27.0	1,034
172	Preeclampsia: A renal perspective. Kidney International, 2005, 67, 2101-2113.	5.2	250
173	The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. British Journal of Haematology, 2005, 128, 303-309.	2.5	155
174	Management of thrombosis in cancer: primary prevention and secondary prophylaxis. British Journal of Haematology, 2005, 128, 291-302.	2.5	97
175	Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. British Journal of Cancer, 2005, 92, 350-358.	6.4	50
176	Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive		
	oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. British Journal of Cancer, 2005, 92, 1696-1701.	6.4	27
177	oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. British Journal of Cancer, 2005, 92, 1696-1701. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Therapy, 2005, 12, 673-681.	6.4 4.6	27 87

<u> </u>		<u> </u>	
( 15	ГАТІ	NEDC	DT
	IAL	NLPC	ואר

#	Article	IF	CITATIONS
179	Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in Oncology, 2005, 32, 61-68.	2.2	34
180	Preclinical Experience With Docetaxel in Gastrointestinal Cancers. Seminars in Oncology, 2005, 32, 3-9.	2.2	12
181	The Role of Bevacizumab as First-line Therapy for Colon Cancer. Seminars in Oncology, 2005, 32, 43-47.	2.2	42
182	Adjuvant Therapy of Stage II and III Colon Cancer. Seminars in Oncology, 2005, 32, 11-14.	2.2	33
184	Philinopside a, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. International Journal of Cancer, 2005, 114, 843-853.	5.1	99
185	Risk factors for chemotherapyâ€associated venous thromboembolism in a prospective observational study. Cancer, 2005, 104, 2822-2829.	4.1	475
186	Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. Journal of Surgical Oncology, 2005, 90, 249-259.	1.7	23
187	PTK 787/ZK 222584, a Tyrosine Kinase Inhibitor of all Known VEGF Receptors, Represses Tumor Growth with High Efficacy. ChemBioChem, 2005, 6, 550-557.	2.6	58
188	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. Critical Reviews in Oncology/Hematology, 2005, 55, 67-81.	4.4	24
189	Novel Therapeutics in Colorectal Cancer. Diseases of the Colon and Rectum, 2005, 48, 1632-1650.	1.3	20
190	Antibody-based targeted therapy for gastric cancer. Gastric Cancer, 2005, 8, 206-208.	5.3	10
192	Operative Salvage for Locoregional Recurrent Colon Cancer After Curative Resection: An Analysis of 100 Cases. Diseases of the Colon and Rectum, 2005, 48, 897-909.	1.3	119
193	Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clinical and Translational Oncology, 2005, 7, 150-155.	2.4	15
194	Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenterology, 2005, 8, 239-247.	0.8	9
195	Targeted therapies for gynecologic malignancies. Current Treatment Options in Oncology, 2005, 6, 121-132.	3.0	3
196	Second-line therapy for advanced colorectal cancer. Current Colorectal Cancer Reports, 2005, 1, 7-12.	0.5	0
197	New developments in therapy for metastatic colorectal cancer. Current Colorectal Cancer Reports, 2005, 1, 13-17.	0.5	0
198	Using biologic markers to optimize therapies. Current Colorectal Cancer Reports, 2005, 1, 18-23.	0.5	0

#	Article	IF	CITATIONS
199	Optimizing adjuvant therapy for colon cancer: Ongoing investigations. Current Colorectal Cancer Reports, 2005, 1, 27-33.	0.5	0
200	The integration of biologic agents into the current systemic management of rectal cancer. Current Colorectal Cancer Reports, 2005, 1, 58-62.	0.5	Ο
201	Systemic coagulation parameters in mice after treatment with vascular targeting agents. Thrombosis Journal, 2005, 3, 21.	2.1	8
202	Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Colorectal Cancer: Limitations and Calls for More Research. Oncology Issues, 2005, 20, 22-24.	0.1	0
203	Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study. Journal of Clinical Oncology, 2005, 23, 3104-3111.	1.6	129
204	New Chemotherapeutic Strategies in Colorectal Cancer. , 2005, 165, 250-259.		12
205	Targeting the VEGF/VEGFR Axis for Cancer Therapy. , 2005, , 429-440.		0
206	Hypertension Associated With Bevacizumab. Clinical Journal of Oncology Nursing, 2005, 9, 407-411.	0.6	13
207	Advanced Colorectal Cancer: Current Treatment and Nursing Management With Economic Considerations. Clinical Journal of Oncology Nursing, 2005, 9, 541-552.	0.6	22
208	Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets, 2005, 5, 229-248.	1.6	48
209	Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies. Current Cancer Drug Targets, 2005, 5, 573-578.	1.6	22
210	Kinases as Drug Discovery Targets in Hematologic Malignancies. Current Molecular Medicine, 2005, 5, 625-642.	1.3	27
211	CHEMORADIOTHERAPY FOR COLORECTAL CANCER. Gut, 2005, 54, 1194-1202.	12.1	76
212	Antivascular Endothelial Growth Factor Monoclonal Antibody Therapy: A Promising Paradigm in Colorectal Cancer. Clinical Journal of Oncology Nursing, 2005, 9, 55-60.	0.6	12
213	Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncológica, 2005, 44, 203-217.	1.8	44
214	Therapeutic Options in the Management of Colon Cancer: 2005 Update. Clinical Journal of Oncology Nursing, 2005, 9, 31-44.	0.6	42
215	Immunotherapy: Basic Guidelines. , 2005, , 88-101.		0
216	Receptor Tyrosine Kinases and Anticancer Therapy. Current Pharmaceutical Design, 2005, 11, 1139-1149.	1.9	42

#	Article	IF	CITATIONS
217	FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology, 2005, 16, iv56-iv60.	1.2	13
218	Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Molecular Cancer Therapeutics, 2005, 4, 956-967.	4.1	37
219	Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale. Journal of Clinical Oncology, 2005, 23, 4866-4875.	1.6	693
220	Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 3502-3508.	1.6	620
221	Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut, 2005, 54, 666-672.	12.1	99
222	Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients. Journal of Clinical Oncology, 2005, 23, 8136-8139.	1.6	410
223	Whither Irinotecan?. Journal of Clinical Oncology, 2005, 23, 4811-4814.	1.6	13
224	CORRECTION. Gut, 2005, 54, 1050-1050.	12.1	5
225	The Novel Gene EG-1 Stimulates Cellular Proliferation. Cancer Research, 2005, 65, 6159-6166.	0.9	23
226	Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics. International Journal of Toxicology, 2005, 24, 357-363.	1.2	13
227	Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival. Clinical Cancer Research, 2005, 11, 4754-4760.	7.0	60
228	Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy. Cancer Research, 2005, 65, 3643-3655.	0.9	171
229	Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy. Journal of Clinical Oncology, 2005, 23, 2574-2576.	1.6	120
230	Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer. Oncologist, 2005, 10, 250-261.	3.7	130
231	The development of clinical research in CRC. Annals of Oncology, 2005, 16, iv37-iv43.	1.2	14
233	Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC). Current Medicinal Chemistry, 2005, 12, 277-296.	2.4	17
234	Current stage-specific chemotherapeutic options in colon cancer. Expert Review of Anticancer Therapy, 2005, 5, 695-704.	2.4	10
235	Quantitative Assessment of Colorectal Cancer Perfusion Using MDCT: Inter- and Intraobserver Agreement. American Journal of Roentgenology, 2005, 185, 225-231.	2.2	68

0	 	<b>D</b> -	
	$1 \cap N$	RE	דעהט
$\sim$			

#	Article	IF	CITATIONS
236	Reducing the Risks of Gastrointestinal Bleeding with Antiplatelet Therapies. New England Journal of Medicine, 2005, 352, 287-289.	27.0	47
237	Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro-Oncology, 2005, 7, 246-253.	1.2	107
238	Inhibition of angiogenesis in cancer patients. Expert Opinion on Emerging Drugs, 2005, 10, 403-412.	2.4	19
239	Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Pharmacogenomics, 2005, 6, 603-614.	1.3	15
240	New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opinion on Investigational Drugs, 2005, 14, 1-17.	4.1	33
241	Bevacizumab Combined with Standard Fluoropyrimidine-Based Chemotherapy Regimens to Treat Colorectal Cancer. Oncology, 2005, 69, 17-24.	1.9	56
242	Monoclonal antibody therapy of ovarian cancer. Expert Review of Anticancer Therapy, 2005, 5, 87-96.	2.4	15
243	Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. Expert Review of Anticancer Therapy, 2005, 5, 681-694.	2.4	5
244	The biology of vascular endothelial growth factors. Cardiovascular Research, 2005, 65, 550-563.	3.8	680
245	PE, a new sulfated saponin from sea cucumber, Exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biology and Therapy, 2005, 4, 874-882.	3.4	133
246	In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models. Clinical Cancer Research, 2005, 11, 3633-3641.	7.0	170
247	Careful Decoy Receptor Titering is Required to Inhibit Tumor Angiogenesis While Avoiding Adversely Altering VEGF Bioavailability. Molecular Therapy, 2005, 11, 300-310.	8.2	20
248	Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice Oncology, 2005, 2, 562-577.	4.3	186
249	Targeted Drug Delivery in Cancer Therapy. Technology in Cancer Research and Treatment, 2005, 4, 363-374.	1.9	259
250	Bevacizumab Plus Fluorouracil: The Value of Being Part of a Developing Story. Journal of Clinical Oncology, 2005, 23, 3660-3662.	1.6	12
251	Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 8033-8040.	1.6	439
252	Delivery of Antiangiogenic Agents for Cancer Gene Therapy. Technology in Cancer Research and Treatment, 2005, 4, 331-341.	1.9	5
253	The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression. Cancer Biology and Therapy, 2005, 4, 371-376.	3.4	266

#	Article	IF	CITATIONS
254	Antibodyâ€Based Therapies for Colorectal Cancer. Oncologist, 2005, 10, 701-709.	3.7	42
257	In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna. Clinical Cancer Research, 2005, 11, 6218-6225.	7.0	25
258	Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model. Clinical Cancer Research, 2005, 11, 2337-2344.	7.0	24
259	A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs: Fig. 1 Clinical Cancer Research, 2005, 11, 7589-7592.	7.0	16
260	VEGF as a Target of Therapy in Gastrointestinal Oncology. Digestive Surgery, 2005, 22, 282-293.	1.2	6
261	Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner. Cancer Research, 2005, 65, 5864-5871.	0.9	178
262	Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma. Clinical Cancer Research, 2005, 11, 4818-4826.	7.0	73
263	Molecularly Targeted Therapy for Gastrointestinal Cancer. Current Cancer Drug Targets, 2005, 5, 171-193.	1.6	83
264	Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions. Journal of Clinical Oncology, 2005, 23, 1295-1311.	1.6	196
265	Novel targeted therapies in the treatment of gastric and esophageal cancer. Annals of Oncology, 2005, 16, 1740-1748.	1.2	69
266	Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence. Journal of Clinical Oncology, 2005, 23, 4553-4560.	1.6	281
267	Low dose versus high dose imatinib for gastrointestinal stromal tumors. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 76-77.	1.7	0
268	Immunohistochemical Expression of Vascular Endothelial Growth Factor and Microvessel Counting as Prognostic Indicators in Node-Negative Colorectal Cancer. Tumor Biology, 2005, 26, 1-8.	1.8	14
269	Effect of Maternal Administration of Selective Cyclooxygenase (COX)-2 Inhibitors on Renal Size, Growth Factors, Proteinases, and COX-2 Secretion in the Fetal Rabbit. Neonatology, 2005, 87, 246-253.	2.0	5
270	Managing Patients Treated with Bevacizumab Combination Therapy. Oncology, 2005, 69, 25-33.	1.9	265
272	Medicinal Benefits of Green Tea: Part II. Review of Anticancer Properties. Journal of Alternative and Complementary Medicine, 2005, 11, 639-652.	2.1	159
273	Prognostic Impact of Race and Ethnicity in the Treatment of Colorectal Cancer. Medical Clinics of North America, 2005, 89, 1045-1057.	2.5	5
275	Chemotherapy for Colorectal Cancer. Digestive Surgery, 2005, 22, 401-414.	1.2	53

#	Article	IF	CITATIONS
276	Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications. Journal of Clinical Oncology, 2005, 23, 3243-3256.	1.6	244
277	Anti-Angiogenic Treatment of Gastrointestinal Malignancies. Cancer Investigation, 2005, 23, 712-726.	1.3	19
278	Antibody-based antiangiogenic cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 1235-1245.	3.4	6
279	Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2005, 14, 607-628.	4.1	17
280	Bevacizumab in colorectal cancer: profile report. Drugs and Therapy Perspectives, 2005, 21, 5-6.	0.6	0
281	Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 3706-3712.	1.6	644
282	Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. Journal of Clinical Oncology, 2005, 23, 3697-3705.	1.6	876
283	Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas. Journal of Clinical Oncology, 2005, 23, 7135-7142.	1.6	244
284	Bevacizumab in the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2005, 5, 997-1005.	3.1	52
285	Black Raspberry Extract and Fractions Contain Angiogenesis Inhibitors. Journal of Agricultural and Food Chemistry, 2005, 53, 3909-3915.	5.2	80
286	Synthesis and Structureâ^'Activity Relationships of Pyrazine-Pyridine Biheteroaryls as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4892-4909.	6.4	32
287	Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia. Hypertension, 2005, 46, 1077-1085.	2.7	342
288	Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. Journal of Hepatology, 2005, 42, 7-11.	3.7	45
289	Targeted therapy for colorectal cancer: mapping the way. Trends in Molecular Medicine, 2005, 11, 327-335.	6.7	19
290	Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 2005, 333, 328-335.	2.1	875
291	Growth factors and their relationship to neoplastic and paraneoplastic disease. European Journal of Internal Medicine, 2005, 16, 83-94.	2.2	3
292	Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 122, 33-39.	1.1	168
293	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthalmology, 2005, 112, 1035-1047.e9.	5.2	626

#	Article	IF	CITATIONS
294	Molecular, Cellular, and Developmental Biology of Breast Cancer. , 2005, , 27-41.		0
295	The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, , 209-231.		195
296	Clinical Management of Oxaliplatin-Associated Neurotoxicity. Clinical Colorectal Cancer, 2005, 5, S38-S46.	2.3	163
297	Targeted therapy in colorectal cancer: do we know enough?. Digestive and Liver Disease, 2005, 38, 71-7.	0.9	7
298	2-Hydroxy-4,6-diamino-[1,3,5]triazines: A Novel Class of VEGF-R2 (KDR) Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 1717-1720.	6.4	53
299	Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer. Oncology, 2005, 69, 46-56.	1.9	79
300	The Future Development of Bevacizumab in Colorectal Cancer. Oncology, 2005, 69, 34-45.	1.9	10
301	Synthesis and Discovery of Pyrazineâ^'Pyridine Biheteroaryl as a Novel Series of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 1886-1900.	6.4	36
302	Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia. Pediatric Research, 2005, 57, 1R-7R.	2.3	217
303	Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma. American Journal of Cancer, 2005, 4, 159-168.	0.4	0
304	Current Advancements in Hard-To-Treat Cancers. American Journal of Cancer, 2005, 4, 105-113.	0.4	1
305	Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. American Journal of Cancer, 2005, 4, 15-34.	0.4	4
306	Management of Metastatic Colorectal Cancer. Disease Management and Health Outcomes, 2005, 13, 137-149.	0.4	4
307	Bevacizumab—current status and future directions. Annals of Oncology, 2005, 16, 999-1004.	1.2	83
308	Angiogenic Factors in the Pathogenesis of Preeclampsia. Current Topics in Developmental Biology, 2005, 71, 297-312.	2.2	65
309	2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as Covalent-Binding, Irreversible Inhibitors of the Kinase Domain of Vascular Endothelial Growth Factor Receptor-2. Journal of Medicinal Chemistry, 2005, 48, 7560-7581.	6.4	59
310	TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS. Annual Review of Pharmacology and Toxicology, 2005, 45, 357-384.	9.4	115
311	Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 17, 3-18.	1.5	332

#	Article	IF	CITATIONS
313	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clinical Practice Oncology, 2006, 3, 24-40.	4.3	968
314	Optimal treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 801-812.	2.4	16
315	Spotlight on Bevacizumab in Advanced Colorectal Cancer, Breast Cancer, and Non-Small Cell Lung Cancer1. BioDrugs, 2006, 20, 193-195.	4.6	26
316	Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opinion on Biological Therapy, 2006, 6, 1175-1192.	3.1	18
317	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. Expert Opinion on Emerging Drugs, 2006, 11, 665-683.	2.4	1
318	Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opinion on Biological Therapy, 2006, 6, 1229-1235.	3.1	29
319	The safety of bevacizumab. Expert Opinion on Drug Safety, 2006, 5, 289-301.	2.4	30
320	Laminin α2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma. American Journal of Pathology, 2006, 168, 991-1003.	3.8	11
321	Vascular Endothelial Growth Factor Localization in the Adult. American Journal of Pathology, 2006, 168, 639-648.	3.8	246
322	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK. Lancet Oncology, The, 2006, 7, 807-808.	10.7	5
322 323	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK. Lancet Oncology, The, 2006, 7, 807-808. Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.	10.7 0.2	5
322 323 324	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.	10.7 0.2 4.4	5 1 22
322 323 324 325	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.         The Molecular Biology of Pulmonary Metastasis. Thoracic Surgery Clinics, 2006, 16, 115-124.	10.7 0.2 4.4 1.0	5 1 22 29
322 323 324 325 326	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.         The Molecular Biology of Pulmonary Metastasis. Thoracic Surgery Clinics, 2006, 16, 115-124.         Adverse Effects of Bevacizumab and Their Management in Solid Tumors. Supportive Cancer Therapy, 2006, 3, 247-250.	10.7 0.2 4.4 1.0	5 1 22 29 17
322 323 324 325 325 326	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.         The Molecular Biology of Pulmonary Metastasis. Thoracic Surgery Clinics, 2006, 16, 115-124.         Adverse Effects of Bevacizumab and Their Management in Solid Tumors. Supportive Cancer Therapy, 2006, 3, 247-250.         New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America, 2006, 86, 1023-1043.	<ol> <li>10.7</li> <li>0.2</li> <li>4.4</li> <li>1.0</li> <li>0.3</li> <li>1.5</li> </ol>	5 1 22 29 17 8
322 323 324 325 325 326 327	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.         The Molecular Biology of Pulmonary Metastasis. Thoracic Surgery Clinics, 2006, 16, 115-124.         Adverse Effects of Bevacizumab and Their Management in Solid Tumors. Supportive Cancer Therapy, 2006, 3, 247-250.         New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America, 2006, 86, 1023-1043.         A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 363-367.	<ol> <li>10.7</li> <li>0.2</li> <li>4.4</li> <li>1.0</li> <li>0.3</li> <li>1.5</li> <li>2.3</li> </ol>	5 1 22 29 17 8
<ul> <li>322</li> <li>323</li> <li>324</li> <li>325</li> <li>326</li> <li>327</li> <li>328</li> <li>329</li> </ul>	Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.         Lancet Oncology, The, 2006, 7, 807-808.         Hypertension therapy for the oncology patient. Community Oncology, 2006, 3, 94-99.         Advances in Chemotherapy for Colorectal Cancer. Clinical Castroenterology and Hepatology, 2006, 4, 808-821.         The Molecular Biology of Pulmonary Metastasis. Thoracic Surgery Clinics, 2006, 16, 115-124.         Adverse Effects of Bevacizumab and Their Management in Solid Tumors. Supportive Cancer Therapy, 2006, 3, 247-250.         New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America, 2006, 86, 1023-1043.         A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 363-367.         Estimating Costs of Care for Patients with Newly Diagnosed Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 52-58.	<ol> <li>10.7</li> <li>0.2</li> <li>4.4</li> <li>1.0</li> <li>0.3</li> <li>1.5</li> <li>2.3</li> <li>2.3</li> </ol>	<ul> <li>5</li> <li>1</li> <li>22</li> <li>29</li> <li>17</li> <li>8</li> <li>28</li> <li>46</li> </ul>

#	Article	IF	CITATIONS
331	Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opinion on Drug Safety, 2006, 5, 553-566.	2.4	100
332	Enzyme Specific Activation of Benzoquinone Ansamycin Prodrugs Using HuCC49ΔCH2â^´Î²-Galactosidase Conjugates. Journal of Medicinal Chemistry, 2006, 49, 6290-6297.	6.4	26
333	Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics, 2006, 28, 1779-1802.	2.5	473
334	Predicting the outcome of chemotherapy for colorectal cancer. Current Opinion in Pharmacology, 2006, 6, 332-336.	3.5	23
335	Metastatic colorectal cancer. Cancer Treatment Reviews, 2006, 32, 557-571.	7.7	11
336	Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: The state of the art. Cancer Treatment Reviews, 2006, 32, 607-618.	7.7	29
337	Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination. European Journal of Cancer, 2006, 42, 467-472.	2.8	47
338	The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. European Journal of Cancer, 2006, 42, 3127-3139.	2.8	314
339	Hypertension Complicating Cancer Chemotherapy. Journal of Clinical Hypertension, 2006, 8, 526-529.	2.0	2
340	Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2006, 113, 992-1001.e6.	5.2	239
341	Chemotherapy-induced thrombosis. Thrombosis Research, 2006, 118, 555-568.	1.7	320
342	Angiogenesis: from plants to blood vessels. Trends in Pharmacological Sciences, 2006, 27, 297-309.	8.7	218
343	Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents. Update on Cancer Therapeutics, 2006, 1, 159-173.	0.4	5
344	Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics, 2006, 1, 353-365.	0.4	1
345	Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 250-253.	1.6	35
346	Monoclonal antibody therapy. Frontiers in Bioscience - Landmark, 2006, 11, 1620.	3.0	45
347	Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study. , 2006, 47, 4569.		158
350	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. , 2006, , 1-29.		4

	CITATION R	EPORT	
#	Article	IF	CITATIONS
352	Drug Development for Advanced Colorectal Cancer in the United States. , 2006, , 317-336.		0
353	Drug Development for Advanced Colorectal Cancer in the United States. , 2006, , 317-335.		0
354	The Role of Radiotherapy in the Treatment of Rectal Cancer. , 2006, , 195-228.		0
355	Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. International Journal of Oncology, 2006, 29, 357.	3.3	14
356	Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. International Journal of Molecular Medicine, 2006, 17, 937.	4.0	20
357	TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN). Retina, 2006, 26, 257-261.	1.7	287
358	Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anti-Cancer Drugs, 2006, 17, 1227-1229.	1.4	45
359	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE) TJ E	TQq1 1 0. 1:7	.784314 rg81 237
360	Protein and Peptide Drugs to Suppress Tumor Angiogenesis. , 2006, , 255-284.		0
361	Trophoblast and pre-eclampsia. , 0, , 194-222.		0
362	Predicting benefit from anti-angiogenic agents in malignancy. Nature Reviews Cancer, 2006, 6, 626-635.	28.4	220
363	Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors. Cancer Gene Therapy, 2006, 13, 993-1001.	4.6	21
364	VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney International, 2006, 69, 1741-1748.	5.2	26
365	Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney International, 2006, 69, 1986-1995.	5.2	91
366	Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. Journal of Physiology, 2006, 570, 141-156.	2.9	29
367	Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology, 2006, 57, 79-101.	4.4	16
368	Novel targets in gastric and esophageal cancer. Critical Reviews in Oncology/Hematology, 2006, 59, 128-138.	4.4	26
369	Targeting VEGF in Cancer Therapy. Current Problems in Cancer, 2006, 30, 7-32.	2.0	26

#	Article	IF	CITATIONS
370	Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. International Journal of Radiation Oncology Biology Physics, 2006, 64, 15-25.	0.8	40
371	Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2006, 13, 353-362.	1.5	59
372	A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance. Investigational New Drugs, 2006, 24, 299-304.	2.6	10
373	Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Investigational New Drugs, 2006, 24, 99-110.	2.6	13
374	Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunology, Immunotherapy, 2006, 55, 481-494.	4.2	42
375	Inhibitors of angiogenesis. Clinical and Translational Oncology, 2006, 8, 475-481.	2.4	4
376	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. Targeted Oncology, 2006, 1, 23-33.	3.6	1
377	Hypertension and targeted therapy. Targeted Oncology, 2006, 1, 104-108.	3.6	9
378	Phase I and II clinical trial design for targeted agents. Targeted Oncology, 2006, 1, 220-227.	3.6	2
379	Targeted therapies in colorectal cancer: Complications and management. Current Colorectal Cancer Reports, 2006, 2, 125-133.	0.5	2
380	Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecologic Oncology, 2006, 102, 134-139.	1.4	91
381	Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management. Journal of Surgical Education, 2006, 63, 334-337.	0.7	92
382	Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1765, 155-177.	7.4	31
383	Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 184-196.	7.4	106
384	Metastatic colorectal cancer. Gastroenterologie Clinique Et Biologique, 2006, 30, 30-42.	0.9	7
386	Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events. Seminars in Oncology, 2006, 33, S26-S34.	2.2	165
387	Future Directions in Vascular Endothelial Growth Factor–Targeted Therapy for Metastatic Colorectal Cancer. Seminars in Oncology, 2006, 33, S41-S49.	2.2	13
388	Bevacizumab in Combination With Chemotherapy: First-Line Treatment of Patients With Metastatic Colorectal Cancer. Seminars in Oncology, 2006, 33, S8-S14.	2.2	64

#	Article	IF	CITATIONS
389	Bevacizumab in Older Patients and Patients With Poorer Performance Status. Seminars in Oncology, 2006, 33, S19-S25.	2.2	6
390	The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncology, 2006, 42, 337-342.	1.5	52
391	Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. British Journal of Surgery, 2006, 93, 1456-1463.	0.3	50
392	Development of antibody-based therapeutics for oncology indications. Drug Development Research, 2006, 67, 699-728.	2.9	3
393	Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. International Journal of Cancer, 2006, 119, 2795-2802.	5.1	57
394	Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews, 2006, 26, 483-530.	10.5	146
395	Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer. Clinical Cancer Research, 2006, 12, 29-33.	7.0	89
396	Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 1251-1271.	1.8	3
397	Quantitative Assessment of Tissue Perfusion Using MDCT: Comparison of Colorectal Cancer and Skeletal Muscle Measurement Reproducibility. American Journal of Roentgenology, 2006, 187, 164-169.	2.2	70
398	ÂBevacizumab and Âcetuximab for colorectal cancer. Drug and Therapeutics Bulletin, 2006, 44, 37-40.	0.3	1
400	Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncology, 2006, 2, 101-110.	2.4	10
401	Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Molecular Cancer Therapeutics, 2006, 5, 1950-1957.	4.1	45
402	Monoclonal Antibodies in the Management of Solid Tumors. Current Topics in Medicinal Chemistry, 2006, 6, 1687-1705.	2.1	22
403	Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine. Current Pharmaceutical Design, 2006, 12, 2397-2408.	1.9	43
404	Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon Cancer. Cancer Investigation, 2006, 24, 98-105.	1.3	9
405	Endoscopic Oncology. , 2006, , .		0
406	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. Nature Clinical Practice Oncology, 2006, 3, 22-23.	4.3	1
407	Hypertension and Maternal–Fetal Conflict during Placental Malaria. PLoS Medicine, 2006, 3, e446.	8.4	98

#	Article	IF	CITATIONS
408	VEGF Inhibitors in Cancer Therapy. Current Pharmaceutical Design, 2006, 12, 387-394.	1.9	102
409	Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology. Current Pharmaceutical Design, 2006, 12, 2631-2644.	1.9	31
410	Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology. Current Pharmaceutical Design, 2006, 12, 2623-2630.	1.9	51
411	Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology, 2006, 24, 5201-5206.	1.6	402
412	Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate. Toxicologic Pathology, 2006, 34, 131-147.	1.8	63
413	Recent advances in targeted therapies for colorectal cancer. Journal of Oncology Pharmacy Practice, 2006, 12, 69-73.	0.9	1
414	Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Annals of Oncology, 2006, 17, 35-42.	1.2	46
415	Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer. Journal of Clinical Oncology, 2006, 24, 528-529.	1.6	5
416	A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Annals of Oncology, 2006, 17, 1399-1403.	1.2	120
417	Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy. Advances in Immunology, 2006, 90, 83-131.	2.2	41
419	Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy. Clinical Cancer Research, 2006, 12, 2197-2207.	7.0	142
420	The Present and Future of Angiogenesisâ€Directed Treatments of Colorectal Cancer. Oncologist, 2006, 11, 992-998.	3.7	26
421	Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis, 2006, 27, 1729-1738.	2.8	150
422	OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models. Cancer Research, 2006, 66, 1015-1024.	0.9	69
423	The integration of targeted agents into systemic therapy of metastatic colorectal cancer. Annals of Oncology, 2006, 17, x122-x128.	1.2	6
424	Thromboembolism in Cancer Patients: Pathogenesis and Treatment. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 254-266.	1.7	26
425	PET/CT in the Evaluation of Response to Treatment of Liver Metastases from Colorectal Cancer with Bevacizumab and Irinotecan. Technology in Cancer Research and Treatment, 2006, 5, 37-43.	1.9	59
426	Evolving role of antineoplastic agents in colorectal cancer. American Journal of Health-System Pharmacy, 2006, 63, S4-S11.	1.0	4

#	Article	IF	CITATIONS
427	A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Annals of Oncology, 2006, 17, 1320-1327.	1.2	47
428	Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301. Journal of Clinical Oncology, 2006, 24, 3354-3360.	1.6	178
429	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. , 2006, , 223-268.		61
430	Perspectives of proteomics in acute myeloid leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1663-1675.	2.4	9
431	Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Annals of Oncology, 2006, 17, 1851-1852.	1.2	19
433	Anti-VEGF therapy: a new approach to colorectal cancer therapy. Expert Review of Anticancer Therapy, 2006, 6, 1385-1396.	2.4	14
436	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, 17, 1214-1224.	2.7	163
437	First- and second-line therapy of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 921-930.	2.4	17
438	Putting the brakes on angiogenesis through a novel VEGF–KLH (kinoid) vaccine. Expert Review of Vaccines, 2007, 6, 491-496.	4.4	2
439	Bevacizumab in the management of solid tumors. Expert Review of Anticancer Therapy, 2007, 7, 433-445.	2.4	45
440	Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology, 2007, 2, 369-378.	0.6	4
441	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. Expert Review of Anticancer Therapy, 2007, 7, 1027-1041.	2.4	3
442	Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. British Journal of Ophthalmology, 2007, 91, 785-789.	3.9	30
443	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American Journal of Physiology - Cell Physiology, 2007, 292, C987-C995.	4.6	290
444	Angiogenesis Inhibitors. Drug Selectivity and Target Specificity. Current Pharmaceutical Design, 2007, 13, 2795-2809.	1.9	43
445	Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology, 2007, 9, 354-363.	1.2	101
446	Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers. Journal of Clinical Oncology, 2007, 25, 4033-4042.	1.6	130
447	Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge. Current Pharmaceutical Design, 2007, 13, 3545-3558.	1.9	40

ARTICLE IF CITATIONS Successful Treatment of Leptomeningeal Disease in Colorectal Cancer With a Regimen of Bevacizumab, 448 1.6 18 Temozolomide, and Irinotecan. Journal of Clinical Oncology, 2007, 25, e14-e16. How Should We Pay the Piper When He's Calling the Tune? On the Long-Term Affordability of Cancer 1.6 28 Care in the United States. Journal of Clinical Oncology, 2007, 25, 175-179. 5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic 450 1.9 15 Colorectal Cancer: A Single-Institute Study. Oncology, 2007, 72, 4-9. Colorectal cancer: New advances in immunotherapy. Cancer Biology and Therapy, 2007, 6, 11-17. Targeted inhibition of EG-1 blocks breast tumor growth. Cancer Biology and Therapy, 2007, 6, 936-941. 452 3.4 13 Prevention of Deep Vein Thrombosis in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2007, 2.7 33, 699-706. Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal 454 4.3 2 cancer?. Nature Clinical Practice Oncology, 2007, 4, 214-215. Functional PET imaging in cancer drug development. Future Oncology, 2007, 3, 215-228. 2.4 19 Vascular Endothelial Growth Factor and the Potential Therapeutic Use of Pegaptanib 456 64 (Macugen®) in Diabetic Retinopathy., 2007, 39, 122-148. Panitumumab a novel drug in cancer treatment. Annals of Oncology, 2007, 18, vi16-vi21. 1.2 Adverse Effects on Hemostatic Function of Drugs Used in Hematologic Malignancies. Seminars in 458 2.7 38 Thrombosis and Hemostasis, 2007, 33, 355-364. Targeting the Vascular Endothelial Growth Factor Pathway in the Treatment of Human Malignancy. Immunological Investigations, 2007, 36, 3-23. The new paradigm in the treatment of colorectal cancer: are we hitting the right target?. Expert 460 4.1 9 Opinion on Investigational Drugs, 2007, 16, 311-324. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of 3.7 Advanced Colorectal Cancer. Oncologist, 2007, 12, 443-450. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proceedings 462 193 7.1 of the National Academy of Sciences of the United States of America, 2007, 104, 2837-2842. Role of Intravitreal Bevacizumab in Neovascular Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 487-491. Mammalian Target of Rapamycin Inhibition Halts the Progression of Proteinuria in a Rat Model of 464 6.152 Reduced Renal Mass. Journal of the American Society of Nephrology: JASN, 2007, 18, 2653-2660. Tumor Necrosis Factor  $\hat{I}_{\pm}$  Mediates Homogeneous Distribution of Liposomes in Murine Melanoma that Contributes to a Better Tumor Response. Cancer Research, 2007, 67, 9455-9462.

#	Article	IF	CITATIONS
466	Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy. Oncologist, 2007, 12, 465-477.	3.7	89
467	Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes. Journal of Clinical Oncology, 2007, 25, 2691-2695.	1.6	54
468	Interstitial Nephritis Secondary to Bevacizumab Treatment in Metastatic Leiomyosarcoma. Annals of Pharmacotherapy, 2007, 41, 707-710.	1.9	34
469	Bevacizumab in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4613s-4616s.	7.0	76
470	Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2007, 25, 2369-2376.	1.6	192
471	Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. Oncologist, 2007, 12, 1443-1455.	3.7	297
472	Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth. Cancer Research, 2007, 67, 593-599.	0.9	216
473	Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer. Clinical Cancer Research, 2007, 13, 4474-4481.	7.0	53
474	Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical Specialties. Clinical Cancer Research, 2007, 13, 2400-2405.	7.0	31
475	Morphological and functional evaluation of angiogenesis of a xenografted human sarcoma in nude mice. Laboratory Animals, 2007, 41, 239-246.	1.0	1
476	A Positive Step Forward, but More Needed to Maximize Cost Benefits of New-Generation Cancer Therapies. Journal of Clinical Oncology, 2007, 25, e31-e32.	1.6	7
477	Grading of Diabetic Retinopathy. , 2007, , 291-391.		1
478	ESMO Handbook on Principles of Translational Research. , 2007, , .		1
479	Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy. Journal of Clinical Oncology, 2007, 25, 4793-4799.	1.6	137
480	Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). British Journal of Ophthalmology, 2007, 91, 804-807.	3.9	200
481	Nursing Considerations of Bevacizumab Use in Multiple Tumor Types. Oncology Nursing Forum, 2007, 34, 693-701.	1.2	4
482	Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab. Journal of the National Cancer Institute, 2007, 99, 1232-1239.	6.3	883
486	Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors. Cancer Control, 2007, 14, 285-294.	1.8	145

ARTICLE IF CITATIONS # Antiangiogenic Therapy for Colorectal Cancer., 2007,,. 487 0 INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONS. 488 1.7 180 Retina, 2007, 27, 141-149. Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test 489 1.4 3 with area under the curve analysis. Anti-Cancer Drugs, 2007, 18, 17-21. Sulfoglycolipids as candidate antiangiogenic radiosensitizers. Anti-Cancer Drugs, 2007, 18, 1-5. 490 Predictive and prognostic markers in colorectal cancer. Personalized Medicine, 2007, 4, 295-306. 491 1.5 1 Combined Modality Therapy of Rectal Cancer., 2007, , . Thyroid cancer: are molecular studies making any difference?. Journal of Laryngology and Otology, 494 0.8 2 2007, 121, 917-926. Update in colorectal, hepatobiliary and pancreatic cancers. Update on Cancer Therapeutics, 2007, 2, 0.4 141-156. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in 496 2.8 72 England and Wales. European Journal of Cancer, 2007, 43, 2487-2494. Monoclonal antibodies in the treatment of advanced colorectal cancer. European Journal of Surgical 1.0 Oncology, 2007, 33, S24-S34. Improving the design of phase II trials of cytostatic anticancer agents. Contemporary Clinical Trials, 498 1.8 41 2007, 28, 138-145. Autocrine VEGF Signaling Is Required for Vascular Homeostasis. Cell, 2007, 130, 691-703. 499 28.9 Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of 500 2.5 39 metastatic colorectal cancer in Japan. Clinical Therapeutics, 2007, 29, 2256-2267. Viral serpin, Serp-1, inhibits endogenous angiogenesis in the chicken chorioallantoic membrane model. 1.6 Cardiovascular Pathology, 2007, 16, 191-202 VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in 502 124 6.7 Molecular Medicine, 2007, 13, 223-230. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. Atherosclerosis, 2007, 195, 269-276. 49 Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a 504 10.7 149 meta-analysis. Lancet Oncology, The, 2007, 8, 898-911. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thrombosis Research, 2007, 120, S41-S50.

		CITATION REPORT	
#	ARTICLE	IF	CITATIONS
506	Bevacizumab's role in treating advanced colorectal cancer. Community Oncology, 2007, 4, 295-2	.96. 0.2	0
507	General Principles of Tumor Immunotherapy. , 2007, , .		3
509	First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer. Drugs and Aging, 2007, 24, 223-238.	2.7	13
510	Novel agents in ovarian cancer. Expert Opinion on Investigational Drugs, 2007, 16, 1227-1239.	4.1	9
511	Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previo Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Stu E3200. Journal of Clinical Oncology, 2007, 25, 1539-1544.	ously Idy 1.6	2,159
512	American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolis Prophylaxis and Treatment in Patients With Cancer. Journal of Clinical Oncology, 2007, 25, 5490-	m <b>1.</b> 6	875
513	The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opir on Biological Therapy, 2007, 7, 871-883.	nion 3.1	6
514	A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenes Expert Opinion on Therapeutic Patents, 2007, 17, 1351-1363.	sis. 5.0	3
515	Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma. Paediatric Dru 2007, 9, 81-96.	gs, 3.1	12
516	Pegaptanib sodium for the treatment of ocular vascular disease. Expert Review of Ophthalmology 2007, 2, 45-60.	<sup>/</sup> , 0.6	1
517	Tyrosine Kinase Inhibitors in Pediatric Malignancies. Cancer Investigation, 2007, 25, 606-612.	1.3	11
518	Bevacizumab in the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2007, 7 739-749.	7, 3.1	23
519	Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncology, 2007, 3, 141-14	·8. 2.4	22
520	Bevacizumab for Advanced Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 303-319.	21, 2.2	22
521	Colorectal Cancer. Mayo Clinic Proceedings, 2007, 82, 114-129.	3.0	55
522	FDA Drug Approval Summary: Panitumumab (Vectibixâ"¢). Oncologist, 2007, 12, 577-583.	3.7	184
523	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Molecular Cancer Research, 2007, 5, 203-220.	Agents. 3.4	378
524	A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumo in vivo. Journal of Translational Medicine, 2007, 5, 61.	r growth 4.4	72

ARTICLE IF CITATIONS Fludarabine. Drugs, 2007, 67, 1633-1655. 525 10.9 37 EGFR, HER2 and VEGF Pathways. Drugs, 2007, 67, 2045-2075. The Direct Effects of Anti–Vascular Endothelial Growth Factor Therapy on Tumor Cells. Clinical 527 2.3 10 Colorectal Cancer, 2007, 6, 564-571. Update on Clinical Data Combining Capecitabine with Targeted Agents in Newly Diagnosed Colorectal Cancer. Clinical Colorectal Cancer, 2007, 7, S16-S20. The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat 529 0.8 58 cornea. Anais Da Academia Brasileira De Ciencias, 2007, 79, 389-394. Chemotherapy in Colorectal Cancer - Past, Present and Futuret. Journal of Bangladesh College of Physicians & Surgeons, 2007, 24, 69-74. 0.1 531 Podocyteâ€"Endothelial Interactions., 2007, , 620-626. 0 Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary 4.1 systemic amyloidosis. American journal of Hematology, 2007, 82, 409-413. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using 533 5.1 26 adeno-associated virus serotype 1-derived vector. International Journal of Cancer, 2007, 120, 278-284. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human 534 5.1 prostate tumor angiogenesis. International Journal of Cancer, 2007, 120, 2096-2109. Infectious complications of monoclonal antibodies used in cancer therapy. Cancer, 2007, 109, 535 4.1 86 2182-2189. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. 4.1 Cancer, 2007, 110, 2339-2346. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. 537 2.4 36 Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 1089-1108. Cancer-associated thrombosis. Critical Reviews in Oncology/Hematology, 2007, 62, 126-136. 4.4 146 Phase I Trial of Tipifarnib (R115777) Concurrent With Radiotherapy in Patients with Glioblastoma 539 0.8 46 Multiforme. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1396-1401. IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents 540 14 in prostate tumor rats. Prostate, 2007, 67, 701-713. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene, 2007, 26, 541 5.946 3661-3678. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews 542 28.4 468 Cancer, 2007, 7, 475-485.

#	Article	IF	CITATIONS
543	Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer, 2007, 96, 1166-1169.	6.4	711
544	Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer, 2007, 96, 1788-1795.	6.4	865
545	Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence. Colorectal Disease, 2007, 9, 133-138.	1.4	20
546	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 1-14.	1.5	105
547	Role of novel targeted agents in the treatment of metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 2-11.	1.1	2
548	Adjuvant Treatment of Colorectal Cancer. Ca-A Cancer Journal for Clinicians, 2007, 57, 168-185.	329.8	227
549	Chemotherapy and Antiangiogenic Agents in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, S68-S73.	2.6	8
550	Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer, 2007, 7, 91.	2.6	94
551	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecologic Oncology, 2007, 104, 768-778.	1.4	64
552	Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate. Journal of Controlled Release, 2007, 118, 310-317.	9.9	44
553	Nephrotic Syndrome After Bevacizumab: Case Report and Literature Review. American Journal of Kidney Diseases, 2007, 49, e23-e29.	1.9	84
554	Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis. American Journal of Kidney Diseases, 2007, 49, 186-193.	1.9	577
555	Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension. American Journal of Kidney Diseases, 2007, 50, 203-218.	1.9	170
557	Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases. Annals of Surgical Oncology, 2007, 14, 1336-1346.	1.5	38
558	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Annals of Surgical Oncology, 2007, 14, 759-765.	1.5	161
559	Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer. Annals of Surgical Oncology, 2007, 14, 1860-1869.	1.5	205
560	A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma. Annals of Surgical Oncology, 2007, 14, 2367-2376.	1.5	142
563	Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology, 2007, 60, 151-170.	2.3	77

#	Article	IF	Citations
564	Evidence of Clinical Activity for Cetuximab Combined with Irinotecan in a Patient with Refractory Anal Canal Squamous-Cell Carcinoma: Report of a Case. Diseases of the Colon and Rectum, 2007, 50, 395-398.	1.3	41
565	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis, 2007, 10, 243-258.	7.2	35
568	Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. International Journal of Colorectal Disease, 2007, 22, 457-465.	2.2	18
569	Surrogate biomarkers for anti-angiogenic therapy for advanced colorectal cancer. Current Colorectal Cancer Reports, 2007, 3, 94-98.	0.5	1
570	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. Current Colorectal Cancer Reports, 2007, 3, 109-115.	0.5	1
571	Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology, 2007, 2, 199-210.	3.6	6
572	Surgical Therapy for Colorectal Metastases to the Liver. Journal of Gastrointestinal Surgery, 2007, 11, 1057-1077.	1.7	206
573	Suramin Inhibits Not Only Tumor Growth and Metastasis but Also Angiogenesis in Experimental Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 171-178.	1.7	22
574	Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. International Ophthalmology, 2008, 28, 59-61.	1.4	34
575	Anti-cancer therapies targeting the tumor stroma. Cancer Immunology, Immunotherapy, 2008, 57, 1-17.	4.2	137
576	Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 62, 779-786.	2.3	317
577	The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer. Current Treatment Options in Oncology, 2008, 9, 357-374.	3.0	5
578	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Current Allergy and Asthma Reports, 2008, 8, 63-68.	5.3	14
579	Immunotherapy of colorectal cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 205-210.	0.5	1
580	Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology, 2008, 10, 35-46.	2.4	62
581	Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. Journal of Gastroenterology, 2008, 43, 842-848.	5.1	2
582	Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246, 837-842.	1.9	162
583	Are Phase 2 screening trials in oncology obsolete?. Statistics in Medicine, 2008, 27, 556-567.	1.6	4

#	Article	IF	CITATIONS
584	"Spontaneous,―delayed colon and rectal anastomotic complications associated with bevacizumab therapy. Journal of Surgical Oncology, 2008, 97, 180-185.	1.7	80
585	Treatment with bevacizumab and irinotecan for recurrent highâ€grade glial tumors. Cancer, 2008, 112, 2267-2273.	4.1	144
586	Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: Two case studies. Head and Neck, 2008, 30, 262-266.	2.0	82
587	Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology, 2008, 83, 862-870.	4.1	62
588	Angiogenesis and hypoxic factors in colorectal cancer. Pathology Research and Practice, 2008, 204, 501-510.	2.3	21
589	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1372-1380	0.8	169
590	Circulating endothelial cells in oncology: pitfalls and promises. British Journal of Cancer, 2008, 98, 1731-1735.	6.4	89
591	Noninvasive assessment of cancer response to therapy. Nature Medicine, 2008, 14, 343-349.	30.7	66
592	Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery, 2008, 7, 21-39.	46.4	1,678
593	The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion, 2008, 48, 1959-1965.	1.6	100
594	SELECTIVE TARGETING OF THE TUMOUR VASCULATURE*. ANZ Journal of Surgery, 2008, 78, 955-967.	0.7	11
595	Targeted therapy in colorectal carcinoma: more than a theory. Colorectal Disease, 2008, 10, 209-218.	1.4	9
596	As tests evolve and costs of cancer care rise: reappraising stoolâ€based screening for colorectal neoplasia. Alimentary Pharmacology and Therapeutics, 2008, 27, 697-712.	3.7	71
597	Review article: current management of metastatic colorectal cancer – the evolving impact of targeted drug therapies. Alimentary Pharmacology and Therapeutics, 2008, 27, 997-1005.	3.7	12
598	The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology, 2008, 66, 6-19.	2.4	56
599	Clinical Use of Anti–Vascular Endothelial Growth Factor Monoclonal Antibodies in Metastatic Colorectal Cancer. Pharmacotherapy, 2008, 28, 23S-30S.	2.6	25
601	Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases. Journal of the American College of Surgeons, 2008, 206, 96-106.	0.5	163
602	The Diagnosis and Management of Cardiovascular Disease in Cancer Patients. Current Problems in Cardiology, 2008, 33, 163-196.	2.4	63

#	ARTICLE	IF	CITATIONS
603	Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Archives of Drug Information, 2008, 1, 97-106.	1.6	4
604	Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice Oncology, 2008, 5, 194-204.	4.3	146
605	Locally Advanced and Metastatic Gastric Cancer. Drugs, 2008, 68, 299-317.	10.9	37
606	Bevacizumab. Drugs, 2008, 68, 487-506.	10.9	98
607	Development of Vitreous Haemorrhage during Treatment withÂBevacizumab for MetastaticÂRectal Cancer. Clinical Drug Investigation, 2008, 28, 523-526.	2.2	5
608	Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 144-148.	2.3	31
609	Multitargeted Inhibitors in Lung Cancer: New Clinical Data. Clinical Lung Cancer, 2008, 9, S92-S99.	2.6	10
610	Systemic Treatment of Colorectal Cancer. Gastroenterology, 2008, 134, 1296-1310.e1.	1.3	418
611	Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. European Journal of Cancer, Supplement, 2008, 6, 14-20.	2.2	1
612	Angiogenesis and plastic surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2008, 61, 1425-1437.	1.0	31
613	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology, 2008, 52, 1502-1517.	2.8	390
614	Anticorps anti-VEGF: <code>toxicitÃ</code> et modalitîs Äadministration. , 2008, , 27-37.		0
615	Early Breast Cancer in the Elderly. Drugs and Aging, 2008, 25, 35-45.	2.7	66
616	Molecular Biomethods Handbook. Springer Protocols, 2008, , .	0.3	13
617	Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 250-267.	1.7	32
618	Crystal Structure of Vascular Endothelial Growth Factor-B in Complex with a Neutralising Antibody Fab Fragment. Journal of Molecular Biology, 2008, 384, 1203-1217.	4.2	14
619	Molecular mechanisms of preeclampsia. Microvascular Research, 2008, 75, 1-8.	2.5	252
621	Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. European Journal of Cancer, 2008, 44, 652-662.	2.8	4

#	Article	IF	CITATIONS
622	The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer, 2008, 44, 2350-2356.	2.8	54
623	Venous thromboembolism in cervical cancer. Lancet Oncology, The, 2008, 9, 54-60.	10.7	26
624	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. Journal of Urology, 2008, 180, 94-98.	0.4	157
625	The Implications of Colorectal Cancer Molecular Biology in Clinical Practice. Surgical Oncology Clinics of North America, 2008, 17, 341-355.	1.5	7
627	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	1.5	12
628	Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer. Surgical Oncology Clinics of North America, 2008, 17, 357-376.	1.5	1
629	Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies. Surgical Oncology Clinics of North America, 2008, 17, 857-876.	1.5	12
630	Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 701-715.	1.8	18
631	Spotlight on Bevacizumab in MetastaticÂColorectal Cancerâ€. BioDrugs, 2008, 22, 339-341.	4.6	3
632	Epidemiology and Management Options for Colorectal Cancer in Children. Paediatric Drugs, 2008, 10, 177-192.	3.1	46
633	VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines. Journal of Interferon and Cytokine Research, 2008, 28, 553-562.	1.2	28
634	<i>Vascular Endothelial Growth Factor</i> Polymorphisms â^1154 G/A and â^460 C/T Are Not Associated with <i>VEGF</i> mRNA Expression and Susceptibility to Sporadic Colon Cancer. DNA and Cell Biology, 2008, 27, 569-574.	1.9	33
635	Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 2008, 26, 2013-2019.	1.6	2,735
636	Serotonin Regulates Macrophage-Mediated Angiogenesis in a Mouse Model of Colon Cancer Allografts. Cancer Research, 2008, 68, 5152-5158.	0.9	119
637	Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. Journal of Clinical Oncology, 2008, 26, 3523-3529.	1.6	547
638	Therapy for Unresectable Metastatic Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2008, 19, 216-225.	0.3	0
639	Renal Physiology and Disease in Pregnancy. , 2008, , 2339-2398.		11
640	The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. Journal of Endocrinological Investigation, 2008, 31, 809-819.	3.3	96

#	Article	IF	CITATIONS
641	Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients. JAMA - Journal of the American Medical Association, 2008, 300, 2277.	7.4	683
642	Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice, 2008, 21, 126-137.	1.0	1
643	Napoleone Ferrara and the Saga of Vascular Endothelial Growth Factor. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 1-8.	1.7	12
644	Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies. Journal of Clinical Oncology, 2008, 26, 3665-3667.	1.6	37
646	What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro-Oncology, 2008, 10, 624-630.	1.2	70
647	ACCF/ACC/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation, 2008, 118, 1894-1909.	1.6	563
648	Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206. Cancer Biology and Therapy, 2008, 7, 1547-1554.	3.4	20
649	Role of AGEs in Diabetic Nephropathy. Current Pharmaceutical Design, 2008, 14, 946-952.	1.9	127
650	Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?. European Heart Journal, 2008, 29, 2325-2326.	2.2	28
651	Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future. Current Pharmaceutical Design, 2008, 14, 3820-3834.	1.9	29
652	Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk. Oncology, 2008, 75, 215-223.	1.9	46
653	Systemic and targeted therapy for advanced colon cancer. Expert Review of Gastroenterology and Hepatology, 2008, 2, 135-149.	3.0	49
654	Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy, 2008, 8, 1965-1976.	2.4	5
655	Vascular complications of selected cancer therapies. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 797-805.	3.3	66
656	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology, 2008, 103, 2890-2907.	0.4	137
657	Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases. Journal of Clinical Oncology, 2008, 26, 5254-5260.	1.6	173
658	How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clinical Practice Nephrology, 2008, 4, 503-509.	2.0	18
659	Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice. American Journal of Health-System Pharmacy, 2008, 65, S15-S21.	1.0	14

# 660	ARTICLE Pathogenesis and Clinical Practice in Gastroenterology. , 2008, , .	IF	Citations 0	
662	Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Molecular Cancer Therapeutics, 2008, 7, 704-711.	4.1	35	
663	Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology, 2008, 10, 355-360.	1.2	85	
664	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology, 2008, 10, 300-308.	1.2	88	
665	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics, 2008, 7, 3670-3684.	4.1	311	
666	Challenges in treating older cancer patients: colon cancer. Annals of Oncology, 2008, 19, vii104-vii108.	1.2	2	
667	Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth. Clinical Cancer Research, 2008, 14, 2137-2144.	7.0	82	
668	Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2008, 8, 392-403.	1.6	10	
669	Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 683-688.	2.4	11	
670	Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. Kidney International, 2008, 73, 733-740.	5.2	46	
673	Screening of liver-targeted drugs. Expert Opinion on Drug Discovery, 2008, 3, 643-654.	5.0	3	
674	Managing patients with metastatic colorectal cancer on bevacizumab. British Journal of Nursing, 2008, 17, 944-949.	0.7	17	
675	Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia, 2008, 24, 97-110.	2.5	3	
676	The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). International Journal of Oncology, 0, , .	3.3	0	
677	Salivary protein factors are elevated in breast cancer patients. Molecular Medicine Reports, 0, , .	2.4	32	
678	The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway. Current Clinical Pharmacology, 2008, 3, 132-143.	0.6	175	
679	Pharmacologic Principles of Regional Therapy in the Treatment of Liver Metastases or Primary Liver Tumors. , 2008, , 38-52.		1	
680	Medical Management of Colorectal Liver Metastasis. , 2008, , 222-242.		1	
		CITATION R	EPORT	
-----	---	---------------------------------	-------	-----------
#	Article		IF	Citations
681	Subcutaneous implantable venous access device erosion through the skin in patients tre anti-vascula endothelial growth factor therapy: a case series. Anti-Cancer Drugs, 2008, 1	ated with 9, 217-219.	1.4	17
682	Subconjunctival Bevacizumab Injection for Corneal Neovascularization. Cornea, 2008, 2	7, 142-147.	1.7	127
683	Effect of Subconjunctival Bevacizumab (Avastin) on Experimental Corneal Neovasculariz Guinea Pigs. Cornea, 2008, 27, 357-362.	ation in	1.7	50
684	Biological treatments in cancer. , 0, , 13-22.			0
685	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Bio and Therapy, 2008, 2, 517.	logics: Targets	3.2	11
687	Safety of bevacizumab in mild haemophilia B. Thrombosis and Haemostasis, 2008, 99, 9	63-964.	3.4	10
688	Intravitreal Bevacizumab versus Combined Bevacizumab-Triamcinolone versus Macular L Photocoagulation in Diabetic Macular Edema. European Journal of Ophthalmology, 2008	.aser 3, 18, 941-948.	1.3	91
689	Antiangiogenic Therapy and Ovarian Cancer. Current Women's Health Reviews, 2008, 4	, 33-44.	0.2	0
690	Management of venous thromboembolism in patients with cancer: role of dalteparin. Va and Risk Management, 2008, Volume 4, 279-287.	iscular Health	2.3	12
691	Results of Intravitreal Bevacizumab for Macular Edema with Retinal Vein Occlusion and I Macular Edema. Journal of Korean Ophthalmological Society, 2008, 49, 1275.	Diabetic	0.2	6
692	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. Or Therapy, 0, , 1.	1coTargets and	2.0	4
693	Current use and potential role of bevacizumab in the treatment of gastrointestinal cance Biologics: Targets and Therapy, 2009, , 429.	ers.	3.2	2
694	Oncology Nursing in a New Era: Optimizing Treatment With Bevacizumab. Clinical Journ Nursing, 2009, 13, 564-572.	al of Oncology	0.6	11
695	Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance PLoS ONE, 2009, 4, e4763.	Biomarkers.	2.5	92
696	Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Lengt Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice. Hypertension, 20	:h Mouse )09, 54, 1129-1135.	2.7	79
697	FDA Review of a Panitumumab (Vectibixâ"¢) Clinical Trial for First-Line Treatment of Met Colorectal Cancer. Oncologist, 2009, 14, 284-290.	astatic	3.7	53
698	Treatment of retinal diseases with VEGF antagonists. Progress in Brain Research, 2009, 2	175, 253-267.	1.4	43
699	Toxicity associated with the long-term use of targeted therapies in patients with advanc carcinoma. Expert Review of Anticancer Therapy, 2009, 9, 795-805.	ed renal cell	2.4	31

#	Article	IF	CITATIONS
700	Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Expert Review of Anticancer Therapy, 2009, 9, 763-771.	2.4	4
701	Biological mechanisms of bevacizumab-associated adverse events. Expert Review of Anticancer Therapy, 2009, 9, 999-1007.	2.4	46
702	DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Annals of Oncology, 2009, 20, 1048-1056.	1.2	41
703	Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents. Journal of Clinical Oncology, 2009, 27, 4865-4873.	1.6	200
704	Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics and Gynecology, 2009, 4, 133-147.	0.4	7
705	The selective VEGFR inhibitor PTK787/ZK 222584 represses the activities of VEGFR-negative bone marrow-derived mesenchymal stem cells. Cancer Biology and Therapy, 2009, 8, 1249-1251.	3.4	1
706	Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nature Reviews Urology, 2009, 6, 375-383.	3.8	44
707	Preeclampsia and Soluble fms-Like Tyrosine Kinase 1. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2252-2254.	3.6	49
708	Angiogenesis Inhibition in the Treatment of Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1070-1078.	1.7	6
709	Bevacizumab: current indications and future development for management of solid tumors. Expert Opinion on Biological Therapy, 2009, 9, 507-517.	3.1	61
710	Anti-Angiogenic Cancer Therapy Updates. Current Molecular Medicine, 2009, 9, 954-966.	1.3	3
712	Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Annals of Oncology, 2009, 20, 5-16.	1.2	162
713	Understanding and managing the possible adverse effects associated with bevacizumab. American Journal of Health-System Pharmacy, 2009, 66, 999-1013.	1.0	95
714	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. Oncologist, 2009, 14, 862-870.	3.7	292
715	Pregnancy and the Kidney. , 2009, , 483-513.		1
716	Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer. Oncologist, 2009, 14, 478-488.	3.7	87
717	Anti-angiogenic Therapy Against Gastrointestinal Tract Cancers. Japanese Journal of Clinical Oncology, 2009, 39, 543-551.	1.3	22
718	Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826.	1.6	149

# 719	ARTICLE Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). British Journal of Ophthalmology, 2009, 93, 155-158.	IF 3.9	CITATIONS
720	Cancer and thrombosis: implications of published guidelines for clinical practice. Annals of Oncology, 2009, 20, 1619-1630.	1.2	101
721	Acquired Fanconi Syndrome After Treatment with Capecitabine, Irinotecan, and Bevacizumab. Annals of Pharmacotherapy, 2009, 43, 1370-1373.	1.9	13
722	Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer, 2009, 9, 246.	2.6	31
723	Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer, 2009, 9, 347.	2.6	46
724	The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecologic Oncology, 2009, 114, 424-426.	1.4	37
726	A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. International Journal of Colorectal Disease, 2009, 24, 677-685.	2.2	84
727	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. International Ophthalmology, 2009, 29, 213-224.	1.4	22
728	Evaluation of Hypertension as a Marker of Bevacizumab Efficacy. Journal of Gastrointestinal Cancer, 2009, 40, 101-108.	1.3	34
729	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Current Colorectal Cancer Reports, 2009, 5, 120-125.	0.5	0
730	Integration of surgery and systemic therapy in the management of metastatic renal cancer. Current Urology Reports, 2009, 10, 35-41.	2.2	9
731	Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology, 2009, 4, 67-76.	3.6	28
732	Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer, 2009, 100, 1704-1719.	6.4	89
733	Rectal cancer. Critical Reviews in Oncology/Hematology, 2009, 70, 160-182.	4.4	14
734	A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 242-248.	4.4	15
735	Intricacies of Bevacizumab-Induced Toxicities and Their Management. Annals of Pharmacotherapy, 2009, 43, 490-501.	1.9	172
736	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 2009, 101, 1033-1038.	6.4	154
737	Chemotherapy for operable and advanced colorectal cancer. Cancer Treatment Reviews, 2009, 35, 509-516.	7.7	17

#	Article	IF	CITATIONS
738	Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. European Journal of Cancer, 2009, 45, 1397-1406.	2.8	65
739	Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal?. European Journal of Cancer, 2009, 45, 2452-2461.	2.8	34
740	EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Letters, 2009, 274, 313-318.	7.2	9
741	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
742	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. Survey of Ophthalmology, 2009, 54, 339-348.	4.0	47
745	Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice. Journal of Surgical Research, 2009, 154, 196-202.	1.6	32
747	Risk stratification for cancer-associated venous thromboembolism. Best Practice and Research in Clinical Haematology, 2009, 22, 35-47.	1.7	35
748	Thrombosis associated with angiogenesis inhibitors. Best Practice and Research in Clinical Haematology, 2009, 22, 115-128.	1.7	100
749	Sclerosing cholangitis in the era of target chemotherapy: A possible anti-VEGF effect. Digestive and Liver Disease, 2009, 41, 72-77.	0.9	12
750	GI bleeding: problems that persist. Gastrointestinal Endoscopy, 2009, 70, 225-228.	1.0	22
751	Next generation oncology drug development: opportunities and challenges. Nature Reviews Clinical Oncology, 2009, 6, 259-265.	27.6	64
752	Arterial Thrombosis With Immunomodulatory Derivatives in the Treatment of Multiple Myeloma: A Single-Center Case Series and Review of the Literature. Clinical Lymphoma and Myeloma, 2009, 9, 320-323.	1.4	8
753	Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology, 2009, 20, 1842-1847.	1.2	476
754	The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America, 2009, 89, 1-15.	1.5	13
755	Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs, 2009, 23, 289-304.	4.6	122
757	Molecular Targeted Therapies for Solid Tumors: Management of Side Effects. Oncology Research and Treatment, 2009, 32, 129-138.	1.2	15
758	Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 109.	8.6	8
760	Current management of colorectal hepatic metastasis. Expert Review of Gastroenterology and Hepatology, 2009, 3, 131-144.	3.0	79

#	Article	IF	CITATIONS
761	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology, 2009, 6, 507-518.	27.6	332
762	Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncology, The, 2009, 10, 559-568.	10.7	398
763	Gastrointestinal toxicities of novel agents in cancer therapy. European Journal of Cancer, 2009, 45, 332-342.	2.8	25
764	Evolving Treatment of Advanced Colon Cancer. Annual Review of Medicine, 2009, 60, 207-219.	12.2	120
765	Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America, 2009, 38, 289-303.	2.2	22
766	Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. Journal of Hypertension, 2009, 27, 2297-2309.	0.5	66
767	A Review on Bevacizumab and Surgical Wound Healing. Annals of Plastic Surgery, 2009, 62, 707-709.	0.9	134
768	Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Oncology Reports, 2009, , .	2.6	6
769	Anti-angiogenic therapies for metastatic colorectal cancer. The Cochrane Library, 2009, , CD005392.	2.8	80
770	Can the biology of VEGF and haem oxygenases help solve pre-eclampsia?. Biochemical Society Transactions, 2009, 37, 1237-1242.	3.4	61
771	Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood, 2009, 113, 1598-1607.	1.4	83
773	Malignant Tumors of the Skin. , 2009, , 1134-1155.		0
774	Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin $\hat{I}\pm V$ and integrin $\hat{I}^23$ in human neuroendocrine tumors. Oncology Reports, 2009, , .	2.6	6
775	Recent Advances in the Signal Transduction Targeting of Colorectal Cancer: The Paradigm of Translational Medicine. Current Signal Transduction Therapy, 2009, 4, 6-21.	0.5	0
776	D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagulation and Fibrinolysis, 2009, 20, 170-175.	1.0	64
777	Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies. Current Pharmaceutical Design, 2010, 16, 3921-3931.	1.9	13
778	Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives. Current Clinical Pharmacology, 2010, 5, 166-177.	0.6	8
779	Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Current Vascular Pharmacology, 2010, 8, 102-113.	1.7	41

#	Article	IF	CITATIONS
780	Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 197-204.	1.6	9
781	Strategies for Overcoming Chemotherapy Resistance in Enterohepatic Tumours. Current Molecular Medicine, 2010, 10, 467-485.	1.3	15
782	Nanoparticle Technology: Addressing the Fundamental Roadblocks to Protein Biomarker Discovery. Current Molecular Medicine, 2010, 10, 133-141.	1.3	46
783	Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma. Cell Biology International, 2010, 34, 171-175.	3.0	6
784	Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2010, 16, 220-225.	2.0	4
785	Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab-Based Chemotherapy and Erythropoietin Stimulating Agents. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 36-42.	1.3	12
786	Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Current Opinion in Hematology, 2010, 17, 1.	2.5	22
787	The Challenge of Metastatic Colorectal Cancer. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S5214.	1.3	17
789	Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. Cancer Immunology, Immunotherapy, 2010, 59, 247-256.	4.2	11
790	Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology, 2010, 66, 813-821.	1.9	72
791	Biodistribution of HuCC49ΔCH2-β-galactosidase in colorectal cancer xenograft model. International Journal of Pharmaceutics, 2010, 386, 208-215.	5.2	7
792	A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. International Journal of Pharmaceutics, 2010, 399, 156-162.	5.2	25
793	Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology, 2010, 3, 307-317.	0.8	4
795	Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Targeted Oncology, 2010, 5, 65-72.	3.6	58
796	Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Medical Oncology, 2010, 27, 585-591.	2.5	12
797	Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Medical Oncology, 2010, 27, 807-814.	2.5	9
798	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical and Translational Oncology, 2010, 12, 533-542.	2.4	51
799	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. International Ophthalmology, 2010, 30, 261-266.	1.4	18

#	Article	IF	CITATIONS
800	Venous thromboembolism and cancer: a systematic review. Journal of Thrombosis and Thrombolysis, 2010, 30, 67-78.	2.1	40
801	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs, 2010, 28, 650-658.	2.6	21
802	Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clinical and Experimental Ophthalmology, 2010, 38, 875-884.	2.6	15
803	"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer, 2010, 10, 567.	2.6	41
804	VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer, 2010, 10, 683.	2.6	29
805	The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer, 2010, 116, 3537-3548.	4.1	28
806	Antiangiogenic agents and late anastomotic complications. Journal of Surgical Oncology, 2010, 101, 180-183.	1.7	41
807	Synthesis and structure–activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4674-4686.	3.0	25
808	Optimizing the management of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2010, 75, 15-26.	4.4	5
809	Colon cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 106-133.	4.4	285
810	Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood and Cancer, 2010, 54, 681-686.	1.5	33
811	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (Râ€CHOP). British Journal of Haematology, 2010, 148, 235-244.	2.5	38
812	The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany. European Journal of Cancer Care, 2010, 19, 795-802.	1.5	2
813	Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. British Journal of Cancer, 2010, 103, 1529-1535.	6.4	13
814	A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. British Journal of Cancer, 2010, 103, 1536-1541.	6.4	13
815	Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nature Medicine, 2010, 16, 420-428.	30.7	312
816	Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer: Targets and Therapy, 2010, 2, 37.	1.8	6
817	Targeted Therapies in Epithelial Ovarian Cancer. Cancers, 2010, 2, 88-113.	3.7	12

#	Article		CITATIONS
818	Place des antiangiogéniques dans la prise en charge des cancers colorectaux métastatiques. Cancéro Digest, 2010, , .		0
819	VEGF-A <sub>165</sub> b Is Cytoprotective and Antiangiogenic in the Retina. , 2010, 51, 4273.		71
820	Disseminated Tumor Embolism From Breast Cancer Leading to Multiorgan Failure. Journal of Clinical Oncology, 2010, 28, e180-e183.	1.6	14
821	Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?. Oncologist, 2010, 15, 130-141.	3.7	110
822	Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?. Clinical Cancer Research, 2010, 16, 5956-5962.	7.0	38
823	Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients. Journal of the American Society of Nephrology: JASN, 2010, 21, 1381-1389.	6.1	199
824	Bevacizumab. Oncologist, 2010, 15, 819-825.	3.7	194
825	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 2010, 28, 3191-3198.	1.6	370
826	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncológica, 2010, 49, 287-297.	1.8	259
827	Cost-Effectiveness of Colorectal Cancer Screening in High-Risk Spanish Patients: Use of a Validated Model to Inform Public Policy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2765-2776.	2.5	21
828	mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells. Thrombosis and Haemostasis, 2010, 104, 318-326.	3.4	5
829	Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Therapeutic Advances in Medical Oncology, 2010, 2, 309-317.	3.2	8
830	Vascular Endothelial Growth Factor: Much More than an Angiogenesis Factor. Molecular Biology of the Cell, 2010, 21, 377-379.	2.1	82
831	Assessing oncologic benefit in clinical trials of immunotherapy agents. Annals of Oncology, 2010, 21, 1944-1951.	1.2	51
832	(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor. Oncologist, 2010, 15, 539-547.	3.7	132
833	Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension, 2010, 23, 460-468.	2.0	210
834	Lack of Therapeutic Effect of Ranibizumab in Fellow Eyes After Intravitreal Administration. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 213-216.	1.4	24
835	Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biology and Therapy, 2010, 9, 176-182.	3.4	68

#	Article	IF	CITATIONS
836	Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis. Oncology, 2010, 79, 27-38.	1.9	163
837	Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. Developments in Ophthalmology, 2010, 46, 21-38.	0.1	15
838	Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology, 2010, 78, 329-339.	1.9	121
839	Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response, 2010, 8, dose-response.0.	1.6	95
840	Bevacizumab Safety in Patients with Central Nervous System Metastases. Clinical Cancer Research, 2010, 16, 269-278.	7.0	236
841	Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study. Oncology, 2010, 78, 376-381.	1.9	105
842	PEDF in Angiogenic Eye Diseases. Current Molecular Medicine, 2010, 10, 267-278.	1.3	51
843	Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America, 2010, 39, 601-613.	2.2	22
844	Treatment of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 359-388.	0.1	0
845	The inefficacy of antiangiogenic therapies. Journal of Angiogenesis Research, 2010, 2, 27.	2.9	14
846	A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 102-107.	2.3	18
847	Antiangiogenic Therapy in Colorectal Cancer: Where Are We 5 Years Later?. Clinical Colorectal Cancer, 2010, 9, S7-S15.	2.3	6
848	Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer. Gastroenterology, 2010, 138, 2163-2176.	1.3	85
849	Unusual first presentation of metastatic pancreatic cancer as skin metastases in a burn patient. Burns, 2010, 36, e111-e114.	1.9	8
850	The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates, 2010, 13, 44-56.	14.4	25
851	Venous thromboembolism and prognosis in cancer. Thrombosis Research, 2010, 125, 490-493.	1.7	319
852	Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmologica, 2010, 88, 868-871.	1.1	32
853	Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment. Journal of the Chinese Medical Association, 2010, 73. 281-288.	1.4	27

#	Article	IF	CITATIONS
855	Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thrombosis Research, 2010, 125, S1-S7.	1.7	82
856	Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thrombosis Research, 2010, 125, S55-S57.	1.7	38
857	Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines. Thrombosis Research, 2010, 125, S120-S127.	1.7	38
858	Chemotherapy: Metastatic Disease. , 2010, , 189-222.		0
859	Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Annals of Oncology, 2010, 21, 1152-1162.	1.2	154
860	Testing toxicity of multiple intravitreal injections of bevacizumab in rabbit eyes. Canadian Journal of Ophthalmology, 2010, 45, 386-392.	0.7	19
861	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. Journal of Experimental and Clinical Cancer Research, 2010, 29, 58.	8.6	46
862	A "MiniPool―Approach for Combined Phase IIB/III Trial in Patients With Life-Threatening Disease: An Application of the Closed Testing Principle. Statistics in Biopharmaceutical Research, 2010, 2, 62-71.	0.8	2
863	Optical tomographic imaging of tumor response to anti-angiogenic drugs in small animals. , 2010, , .		0
864	Bevacizumab Plus Irinotecan–Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens. Cancer Investigation, 2010, 28, 33-37.	1.3	16
865	Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncologist, 2010, 15, 1179-1191.	3.7	63
866	Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut, 2010, 59, 838-858.	12.1	45
867	Monitoring of anti-angiogenic drug response with dynamic fluorescence imaging. , 2010, , .		2
868	The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opinion on Biological Therapy, 2011, 11, 405-413.	3.1	34
869	Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies. Journal of Clinical Oncology, 2011, 29, 1757-1764.	1.6	197
870	Genetics of Proteinuria: An Overview of Gene Mutations Associated with Nonsyndromic Proteinuric Glomerulopathies. Advances in Chronic Kidney Disease, 2011, 18, 273-289.	1.4	15
871	Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opinion on Drug Delivery, 2011, 8, 749-763.	5.0	40
872	Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies. Heart Failure Clinics, 2011, 7, 299-311.	2.1	12

		CITATION REP	PORT	
#	Article		IF	CITATIONS
873	Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 135-139.		1.5	16
874	Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-ana Digestive and Liver Disease, 2011, 43, 286-294.	ilysis.	0.9	39
875	Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metasta Colorectal Cancer. Drugs and Aging, 2011, 28, 83-91.	tic	2.7	2
876	Principles of Anticancer Drug Development. , 2011, , .			0
877	Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 1-64.		1.0	120
878	Systemic Therapy for Colon Cancer. , 2011, , 167-183.			0
879	Gastrointestinal Oncology. , 2011, , .			2
880	Development and progression of colorectal neoplasia. Cancer Biomarkers, 2011, 9, 235-265.		1.7	39
881	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 245-257.		2.3	20
882	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. Cytokine, 2011, 115-129.	53,	3.2	17
883	Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serio adverse events in metastatic colorectal cancer. European Journal of Surgical Oncology, 2011, 37, 737-746.	us	1.0	52
884	Contribution of Surface Localization to Platelet Activation by CD154 Antibodies and Introductior Novel Approach for Studying Immune Complex Activity. Thrombosis Research, 2011, 127, 571-57	i of a 75.	1.7	3
885	Prevention of VTE in women with cancer. Thrombosis Research, 2011, 127, S5-S8.		1.7	27
886	New insights into the etiology of preeclampsia: identification of key elusive factors for the vascul complications. Thrombosis Research, 2011, 127, S72-S75.	ar	1.7	113
887	Bevacizumab in the management of colorectal cancer: A review. Journal of Solid Tumors, 2011, 1	, <b>.</b>	0.1	1
889	The Lymphatics: On the Route to Cancer Metastasis. , 0, , 237-254.			0
890	Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic color cancer: a randomized phase III ARTIST trial. Chinese Journal of Cancer, 2011, 30, 682-689.	ectal	4.9	103
891	From the discovery of Vascular Endothelial Growth Factor to the introduction of Avastin in clinica trials - an interview with Napoleone Ferrara. International Journal of Developmental Biology, 2011 383-388.	l , 55,	0.6	37

.

#	Article	IF	CITATIONS
892	Management of cardiac and pulmonary treatment–related side effects. , 2011, , 67-94.		2
893	KRAS Codons 12 and 13 Mutation Analysis: A Comparative Study between Direct Sequencing and a New Sensitive Real-Time PCR Assay. Sequencing, 2011, 2011, 1-7.	0.5	3
894	Relevance of VEGF and Nephrin Expression in Glomerular Diseases. Journal of Signal Transduction, 2011, 2011, 1-9.	2.0	10
895	Colorectal Liver Metastases. International Journal of Surgical Oncology, 2011, 2011, 1-12.	0.6	26
897	Asiatic Acid Inhibits Pro-Angiogenic Effects of VEGF and Human Gliomas in Endothelial Cell Culture Models. PLoS ONE, 2011, 6, e22745.	2.5	59
898	Surgery and Target Agents for Renal Cell Carcinoma Treatment: The Path between Proper Interaction. Urologia, 2011, 78, 9-15.	0.7	0
899	Treatments for Corneal Neovascularization: A Review. Cornea, 2011, 30, 927-938.	1.7	108
900	Treatments for Corneal Neovascularization: A Review. Cornea, 2011, , 1.	1.7	1
901	A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 443-448.	1.3	9
902	Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anti-Cancer Drugs, 2011, 22, 191-197.	1.4	21
903	Bevacizumab and its use in epithelial ovarian cancer. Future Oncology, 2011, 7, 365-379.	2.4	14
904	Is inflammation the cause of pre-eclampsia?. Biochemical Society Transactions, 2011, 39, 1619-1627.	3.4	97
905	Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD). Reviews on Recent Clinical Trials, 2011, 6, 158-170.	0.8	2
906	Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 403-407.	4.9	118
907	Neuroendoscope-Assisted Removal of an Organized Chronic Subdural Hematoma in a Patient on Bevacizumab Therapy-Case Report Neurologia Medico-Chirurgica, 2011, 51, 515-518.	2.2	20
908	Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with <sup>64</sup> Cu″abeled bevacizumab in colorectal cancer xenografts. Cancer Science, 2011, 102, 117-121.	3.9	52
909	Association of soluble fmsâ€like tyrosine kinaseâ€1 with pulmonary hypertension and haemolysis in sickle cell disease. British Journal of Haematology, 2011, 152, 485-491.	2.5	21
911	Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?. Annals of Surgical Oncology, 2011, 18, 733-737.	1.5	31

#	Article	IF	CITATIONS
912	Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. Journal of Neuro-Oncology, 2011, 104, 103-112.	2.9	27
913	Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. Journal of Cancer Research and Clinical Oncology, 2011, 137, 55-63.	2.5	8
914	Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis, 2011, 14, 223-234.	7.2	66
916	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2011, 68, 1207-1213.	2.3	67
917	Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2011, 67, 613-623.	1.9	87
918	Adjuvant 5-Fluorouracil-Induced Colitis Necessitating Completion Colectomy. Journal of Gastrointestinal Cancer, 2011, 42, 275-277.	1.3	2
919	Adjuvant chemotherapy in colon carcinoma stages II and III. Memo - Magazine of European Medical Oncology, 2011, 4, 86-89.	0.5	1
920	Cardiovascular toxicity of anti-angiogenic drugs. Targeted Oncology, 2011, 6, 197-202.	3.6	56
921	Is There a Future for Bevacizumab in the Adjuvant Setting After the C-08 and AVANT Trials?. Current Colorectal Cancer Reports, 2011, 7, 246-251.	0.5	0
922	Jekyll and Hyde: the role of the microenvironment on the progression of cancer. Journal of Pathology, 2011, 223, 163-177.	4.5	309
923	Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors. Journal of Surgical Oncology, 2011, 104, 316-322.	1.7	42
924	Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer, 2011, 117, 343-352.	4.1	116
925	Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology, 2011, 79, 103-111.	4.4	31
926	Anti-Angiogenic Therapy in Uveal Melanoma. Developments in Ophthalmology, 2012, 49, 117-136.	0.1	29
927	Toward Standardized High-Throughput Serum Diagnostics: Multiplex–Protein Array Identifies IL-8 and VEGF as Serum Markers for Colon Cancer. Journal of Biomolecular Screening, 2011, 16, 1018-1026.	2.6	44
928	Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges. Current Medicinal Chemistry, 2011, 18, 1599-1612.	2.4	17
929	Quantitative Assessment of Tumor Blood Flow in Mice after Treatment with Different Doses of an Antiangiogenic Agent with Contrast-enhanced Destruction-Replenishment US. Radiology, 2011, 259, 406-413.	7.3	31
930	Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology, 2011, 22, 1404-1412.	1.2	135

#	Article	IF	CITATIONS
931	Bevacizumab Treatment for Solid Tumors. JAMA - Journal of the American Medical Association, 2011, 305, 506.	7.4	51
932	Treatment-Related Mortality With Bevacizumab in Cancer Patients. JAMA - Journal of the American Medical Association, 2011, 305, 487.	7.4	393
933	Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina. Circulation Research, 2011, 109, 428-436.	4.5	433
934	Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System. Circulation, 2011, 124, 1687-1691.	1.6	112
935	Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells. Clinical Cancer Research, 2011, 17, 6192-6205.	7.0	148
936	Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer. BioDrugs, 2011, 25, 43-50.	4.6	4
937	Safety of Bevacizumab in Patients with Metastatic Breast Cancer. Oncology, 2011, 80, 314-325.	1.9	23
938	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. Current Vascular Pharmacology, 2011, 9, 629-646.	1.7	39
939	Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later. Journal of Clinical Oncology, 2011, 29, 124-126.	1.6	24
940	Antiangiogenesis Enhances Intratumoral Drug Retention. Cancer Research, 2011, 71, 2675-2685.	0.9	47
941	Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase. Molecular Cancer Therapeutics, 2011, 10, 1327-1336.	4.1	21
942	Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy. Molecular Cancer Therapeutics, 2011, 10, 603-614.	4.1	14
943	Pre-Eclampsia, Severe Pre-Eclampsia and Hemolysis, Elevated Liver Enzymes and Low Platelets Syndrome: What is New?. Women's Health, 2011, 7, 555-569.	1.5	17
944	Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British Journal of Cancer, 2011, 105, 44-52.	6.4	31
945	Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer. British Journal of Cancer, 2011, 105, 1693-1696.	6.4	2
946	High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. British Journal of Cancer, 2011, 105, 975-982.	6.4	24
947	Anticoagulant use in cancer patients. Expert Opinion on Pharmacotherapy, 2011, 12, 351-362.	1.8	1
948	VEGF-A and Tenascin-C produced by S100A4 <sup>+</sup> stromal cells are important for metastatic colonization. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16002-16007.	7.1	295

#	Article	IF	CITATIONS
949	A Review of the Treatment Options in Recurrent Glioblastoma: Focus on Bevacizumab. Clinical Medicine Reviews in Oncology, 2011, 3, 79-92.	0.0	0
950	Inhibiting angiogenesis in malignant gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 279-308.	1.8	1
951	AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, Inhibits Angiogenesis in Models of Ocular Neovascular Diseases. , 2012, 53, 2170.		27
952	Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection. Journal of Oncology Pharmacy Practice, 2012, 18, 152-154.	0.9	6
953	Monitoring early tumor response to drug therapy with diffuse optical tomography. Journal of Biomedical Optics, 2012, 17, 016014.	2.6	23
954	Registries and Randomized Trials in Assessing the Effects of Bevacizumab in Colorectal Cancer: Is There a Common Theme?. Journal of Clinical Oncology, 2012, 30, 580-581.	1.6	15
955	Use of bevacizumab in the treatment of metastatic colorectal cancer. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 25-30.	0.5	1
956	Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. Eye, 2012, 26, 958-966.	2.1	8
957	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. British Journal of Cancer, 2012, 106, 1718-1721.	6.4	30
958	Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. British Journal of Cancer, 2012, 107, 308-314.	6.4	38
959	Anti-VEGF Therapies in the Clinic. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006577-a006577.	6.2	196
960	Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer. Oncologist, 2012, 17, 513-524.	3.7	67
961	Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety. Oncologist, 2012, 17, 117-124.	3.7	27
962	The Risk for Anemia with Targeted Therapies for Solid Tumors. Oncologist, 2012, 17, 715-724.	3.7	34
963	An overview of angiogenesis and renal cell carcinoma. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2012, 2, 3.	0.5	7
964	Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management. ISRN Vascular Medicine, 2012, 2012, 1-22.	0.7	10
965	The Current State of Targeted Agents in Rectal Cancer. International Journal of Surgical Oncology, 2012, 2012, 1-14.	0.6	8
966	Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology, 2012, 23, 458-463.	1.2	63

#	Article	IF	CITATIONS
967	Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. Current Pharmaceutical Design, 2012, 18, 2680-2701.	1.9	20
968	Independent Radiologic Review in Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. Radiology, 2012, 263, 86-95.	7.3	4
969	Multidisciplinary Management of Early-Stage Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1577-1585.	4.9	4
970	Infarct-like Necrosis. American Journal of Surgical Pathology, 2012, 36, 570-576.	3.7	52
971	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 2012, 28, 654-658.	2.6	29
972	First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. Oncologist, 2012, 17, 15-25.	3.7	192
973	Treating venous thromboembolism in patients with cancer. Expert Review of Hematology, 2012, 5, 201-209.	2.2	25
974	Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Investigational New Drugs, 2012, 30, 1978-1983.	2.6	8
975	Side effects of anti-angiogenic drugs. Thrombosis Research, 2012, 129, S50-S53.	1.7	103
976	Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer – A two stage phase II clinical trial. Radiotherapy and Oncology, 2012, 102, 10-13.	0.6	70
977	Tumor and Non-Tumor Liver Angiogenesis Is Traced and Evaluated by Hepatic Arterial Ultrasound in Murine Models. Ultrasound in Medicine and Biology, 2012, 38, 1195-1204.	1.5	9
978	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Breast Diseases, 2012, 23, 351-352.	0.0	0
979	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. Clinical Colorectal Cancer, 2012, 11, 229-237.	2.3	18
980	Bevacizumab every 4Âweeks is as effective as every 2Âweeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1845-1852.	2.5	4
981	Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 608-615.	1.6	117
982	Pro- and anti-angiogenic agents. Journal Des Maladies Vasculaires, 2012, 37, 132-139.	0.6	1
983	Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 159-165.	1.7	147
984	Multidetector CT Features of Mesenteric Vein Thrombosis. Radiographics, 2012, 32, 1503-1522.	3.3	56

#	Article	IF	CITATIONS
985	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut, 2012, 61, 1291-1298.	12.1	74
986	Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension. American Journal of Medicine, 2012, 125, 14-22.	1.5	204
987	A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews, 2012, 38, 484-493.	7.7	111
988	Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer, 2012, 11, 38-44.	2.3	29
989	Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer, 2012, 12, 89.	2.6	109
990	An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent. BMC Ophthalmology, 2012, 12, 10.	1.4	10
991	Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. Journal of Hematology and Oncology, 2012, 5, 63.	17.0	97
992	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opinion on Drug Discovery, 2012, 7, 723-743.	5.0	26
993	The impact of magnesium sulfate therapy on angiogenic factors in preeclampsia. Pregnancy Hypertension, 2012, 2, 16-21.	1.4	5
994	Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. British Journal of Cancer, 2012, 107, 287-290.	6.4	34
995	Why do targeted agents not work in the adjuvant setting in colon cancer?. Expert Review of Anticancer Therapy, 2012, 12, 1337-1345.	2.4	11
996	Bevacizumab in colorectal cancer: current and future directions. Expert Review of Anticancer Therapy, 2012, 12, 1263-1273.	2.4	17
997	Major Surgery in Patients with Metastatic Colorectal Cancer in Western Europe. Journal of Gastrointestinal Cancer, 2012, 43, 456-461.	1.3	10
998	A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis. American Journal of Pathology, 2012, 181, 376-379.	3.8	160
999	From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361.	28.4	323
1000	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach – present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	1.5	53
1001	Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature. PLoS ONE, 2012, 7, e35629.	2.5	19
1002	Treatment of Neovascular Age Related Macular Degeneration. , 2012, , .		0

# 1003	ARTICLE Venous Thromboembolism Prophylaxis in Cancer Patients. , 2012, , .	IF	Citations
1004	Usefulness of Bevacizumab with the Treatment of Metastatic Colorectal Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 164-170.	0.0	0
1005	Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncology Reviews, 2012, 6, 6.	1.8	2
1006	Novel anti-angiogenic agents for colorectal cancer. Are we moving on?. Journal of Solid Tumors, 2012, 3, .	0.1	0
1007	Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. OncoTargets and Therapy, 2012, 5, 199.	2.0	5
1008	Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. Neoplasma, 2012, 60, 83-91.	1.6	4
1009	Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World Journal of Gastroenterology, 2012, 18, 637.	3.3	35
1010	Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia. Thrombosis and Haemostasis, 2012, 108, 1-2.	3.4	10
1011	Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. OncoTargets and Therapy, 2012, 5, 133.	2.0	12
1012	Neurotoxicity of Biologically Targeted Agents in Pediatric Cancer Trials. Pediatric Neurology, 2012, 46, 212-221.	2.1	10
1013	Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. Medical Oncology, 2012, 29, 3125-3128.	2.5	9
1014	Bevacizumab: overview of the literature. Expert Review of Anticancer Therapy, 2012, 12, 567-580.	2.4	79
1015	Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers. Current Oncology Reports, 2012, 14, 277-284.	4.0	44
1016	Bevacizumab 5 or 7.5Âmg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10ÂMinutes. Journal of Gastrointestinal Cancer, 2012, 43, 244-248.	1.3	4
1017	Highlights in the adjuvant treatment of colon cancer from annual meetings 2011. Memo - Magazine of European Medical Oncology, 2012, 5, 163-166.	0.5	0
1018	Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. International Journal of Colorectal Disease, 2012, 27, 623-634.	2.2	23
1019	Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea. Clinical Therapeutics, 2012, 34, 1408-1419.	2.5	14
1020	Bevacizumab-Associated Fistula Formation in Postoperative Colorectal Cancer Patients. Journal of the American College of Surgeons, 2012, 214, 582-588.	0.5	33

#	Article	IF	Citations
1021	Principles of cancer treatment by immunotherapy. Surgery, 2012, 30, 198-202.	0.3	1
1022	Biodegradable synthetic polymers: Preparation, functionalization and biomedical application. Progress in Polymer Science, 2012, 37, 237-280.	24.7	1,103
1023	Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology, 2012, 91, 39-46.	1.8	12
1024	5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemotherapy and Pharmacology, 2012, 69, 57-64.	2.3	72
1025	Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clinical and Experimental Metastasis, 2012, 29, 91-99.	3.3	18
1026	Perirenal hematoma associated with bevacizumab treatment. Investigational New Drugs, 2012, 30, 808-809.	2.6	6
1027	Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. Investigational New Drugs, 2012, 30, 653-661.	2.6	5
1028	The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. Journal of Neuro-Oncology, 2012, 106, 81-88.	2.9	17
1029	Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neuro-Oncology, 2012, 107, 351-358.	2.9	47
1030	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2012, 17, 1-29.	2.2	658
1031	Infusion of Bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updates in Surgery, 2013, 65, 121-124.	2.0	13
1032	Perioperative Complications After Neoadjuvant Chemotherapy With and Without Bevacizumab for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2013, 17, 527-532.	1.7	20
1033	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer, 2013, 21, 3243-3254.	2.2	46
1034	Side Effects of Medical Cancer Therapy. , 2013, , .		4
1035	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemotherapy and Pharmacology, 2013, 72, 1-12.	2.3	17
1036	Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy, 2013, 5, 1005-1020.	2.0	4
1037	Cost-Effectiveness of Various Interventions for Newly Diagnosed Diabetic Macular Edema. Ophthalmology, 2013, 120, 1835-1842.	5.2	48
1038	Managing Toxicities Associated With Antiangiogenic Biologic Agents in Combination With Chemotherapy for Metastatic Colorectal Cancer. Clinical Journal of Oncology Nursing, 2013, 17, 425-433.	0.6	24

#	Article	IF	CITATIONS
1039	The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. International Ophthalmology, 2013, 33, 507-513.	1.4	12
1042	Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials. Clinical Drug Investigation, 2013, 33, 779-788.	2.2	30
1043	Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. BMC Cancer, 2013, 13, 454.	2.6	0
1044	Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. International Journal of Clinical Oncology, 2013, 18, 689-695.	2.2	5
1045	Comparative Effectiveness and Cost-Effectiveness of Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies. American Journal of Gastroenterology, 2013, 108, 120-132.	0.4	99
1046	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 29-37.	10.7	997
1047	XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemotherapy and Pharmacology, 2013, 71, 257-264.	2.3	21
1048	Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. Hpb, 2013, 15, 106-115.	0.3	44
1049	Gastric perforation following stereotactic body radiation therapy of hepatic metastasis from colon cancer. Practical Radiation Oncology, 2013, 3, 40-44.	2.1	14
1050	The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 501-509.	1.0	16
1051	Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment. Journal of Dermatological Science, 2013, 70, 116-122.	1.9	22
1052	Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.5	26
1053	Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management. Clinical Colorectal Cancer, 2013, 12, 86-94.	2.3	12
1054	Monoclonal Antibodies in Conditioning Regimens forÂHematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1288-1300.	2.0	11
1055	Prevention of arterial and venous thrombosis in cancer patients. Cor Et Vasa, 2013, 55, e196-e200.	0.1	6
1056	Renal Physiology and Disease in Pregnancy. , 2013, , 2689-2761.		19
1057	Mechanisms of Gastrointestinal Carcinogenesis. Molecular Pathology Library, 2013, , 3-29.	0.1	0
1058	Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Medical Oncology, 2013, 30, 327.	2.5	40

#	Article	IF	CITATIONS
1059	Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression. Oncology Reports, 2013, 29, 73-78.	2.6	16
1060	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 306.	1.9	59
1061	Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management. Current Treatment Options in Oncology, 2013, 14, 389-404.	3.0	20
1062	Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?. Current Colorectal Cancer Reports, 2013, 9, 317-325.	0.5	2
1063	Intravitreal Bevacizumab for Ocular Metastasis of Multiple Myeloma. Optometry and Vision Science, 2013, 90, e236-e240.	1.2	13
1064	Biomarkers for Anti-Angiogenic Therapy in Cancer. International Journal of Molecular Sciences, 2013, 14, 9338-9364.	4.1	58
1065	Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. Current Oncology, 2013, 20, 247-251.	2.2	6
1066	Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. Oncologist, 2013, 18, 1004-1012.	3.7	210
1067	A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research, 2013, 19, 258-267.	7.0	165
1068	Prognostic Significance of COX-2 Expression and Correlation With Bcl-2 and VEGF Expression, Microvessel Density, and Clinical Variables in Classical Hodgkin Lymphoma. American Journal of Surgical Pathology, 2013, 37, 1242-1251.	3.7	34
1069	Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 388-391.	1.3	5
1070	Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08. Journal of the National Cancer Institute, 2013, 105, 989-992.	6.3	56
1071	Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. Clinical Cancer Research, 2013, 19, 4816-4823.	7.0	140
1072	Cardiotoxicity. , 2013, , 483-530.		2
1073	Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. British Journal of Pharmacology, 2013, 170, 712-729.	5.4	202
1074	Acute and severe acne in a patient treated with bevacizumab. International Journal of Dermatology, 2013, 52, 486-490.	1.0	10
1075	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biology and Therapy, 2013, 14, 340-346.	3.4	13
1076	Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III †Stop and Go' Study Results - A Turkish Oncology Group Trial. Oncology, 2013, 85, 328-335.	1.9	59

#	ARTICLE	IF	CITATIONS
 1077	Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 1181-1191.	2.4	10
1078	Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene, 2013, 32, 5449-5457.	5.9	27
1079	Effects of Intraperitoneal Bevacizumab Administration on Colonic Anastomosis and Early Postoperative Adhesion Formation. Surgical Innovation, 2013, 20, 559-565.	0.9	7
1080	Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. International Journal of Oncology, 2013, 43, 1447-1455.	3.3	9
1081	The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. European Journal of Ophthalmology, 2013, 23, 553-557.	1.3	23
1083	Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. OncoTargets and Therapy, 2013, 6, 1393.	2.0	3
1085	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	2.0	7
1086	Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World Journal of Gastroenterology, 2013, 19, 5051.	3.3	84
1087	CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma. PLoS ONE, 2014, 9, e87066.	2.5	46
1089	Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. World Journal of Gastroenterology, 2014, 20, 1993.	3.3	23
1091	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
1092	Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice, 2014, 2014, 1-8.	1.5	19
1093	Risk Assessment for Thrombosis in Cancer. Seminars in Thrombosis and Hemostasis, 2014, 40, 319-324.	2.7	40
1094	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opinion on Biological Therapy, 2014, 14, 1319-1332.	3.1	12
1095	Bevacizumab in the treatment of epithelial ovarian carcinoma. Clinical Investigation, 2014, 4, 535-548.	0.0	0
1096	Biologic agents in the treatment of colorectal cancer: an update. Colorectal Cancer, 2014, 3, 363-374.	0.8	1
1097	Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. Journal of Clinical Pharmacology, 2014, 54, 495-502.	2.0	6
1098	Preeclampsia Is Associated with Lower Production of Vascular Endothelial Growth Factor by Peripheral Blood Mononuclear Cells. Archives of Medical Research, 2014, 45, 561-569.	3.3	13

#	Article	IF	CITATIONS
1099	Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Medical Oncology, 2014, 31, 276.	2.5	4
1100	New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging, 2014, 14, 26.	2.8	13
1101	Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Neuro-Oncology, 2014, 16, 765-767.	1.2	13
1102	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. Pancreas, 2014, 43, 343-349.	1.1	8
1103	Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. Molecular and Clinical Oncology, 2014, 2, 166-170.	1.0	3
1104	Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 322-329.	1.1	10
1105	Incidence and Relevance of Proteinuria in Bevacizumab-Treated Patients: Pooled Analysis from Randomized Controlled Trials. American Journal of Nephrology, 2014, 40, 75-83.	3.1	41
1107	Effect of chemotherapy, radiation, or immunosuppression on the integrity of the intestinal anastomosis. Seminars in Colon and Rectal Surgery, 2014, 25, 105-109.	0.3	3
1108	Complete response of multiple unresectable liver metastases from ascending colon cancer treated with FOLFIRI plus bevacizumab as third-line treatment. International Cancer Conference Journal, 2014, 3, 81-86.	0.5	0
1109	Transarterial chemoembolization of unresectable systemic chemotherapyâ€refractory liver metastases from colorectal cancer: Longâ€term results over a 10â€year period. International Journal of Cancer, 2014, 134, 1225-1231.	5.1	65
1110	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. Clinical Cancer Research, 2014, 20, 2783-2792.	7.0	37
1111	Effects of sFlt-1 and alpha 2-macroglobulin on vascular endothelial growth factor-induced endothelin-1 upregulation in human microvascular endothelial cells. Placenta, 2014, 35, 64-69.	1.5	18
1112	The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, 17, 805-821.	7.2	21
1113	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	4.0	9
1114	Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin. Annals of Surgical Oncology, 2014, 21, 1792-1800.	1.5	70
1115	Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. Critical Reviews in Oncology/Hematology, 2014, 90, 152-164.	4.4	49
1116	VEGFR tyrosine kinase inhibitor II (VRI) induced vascular insufficiency in zebrafish as a model for studying vascular toxicity and vascular preservation. Toxicology and Applied Pharmacology, 2014, 280, 408-420.	2.8	37
1117	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 726-734.	1.9	43

#	Article	IF	CITATIONS
1118	Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. Seminars in Ophthalmology, 2014, 29, 263-275.	1.6	9
1119	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. Oncologist, 2014, 19, 1156-1168.	3.7	90
1120	Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1483-1489.	1.9	36
1121	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational New Drugs, 2014, 32, 700-709.	2.6	4
1122	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investigational New Drugs, 2014, 32, 717-722.	2.6	3
1124	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	2.3	108
1125	Bevacizumab in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 2014, 5, 78-88.	1.0	21
1126	Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 135-144.	2.3	27
1127	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 2014, 46, 561-567.	0.9	16
1128	Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration. Ophthalmology, 2014, 121, 936-945.	5.2	71
1129	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thrombosis Research, 2014, 133, S122-S127.	1.7	44
1130	The use of phase 2 interim analysis to expedite drug development decisions. Contemporary Clinical Trials, 2014, 38, 235-244.	1.8	2
1132	Pre-Existing Antihypertensive Treatment Predicts Early Increase in Blood Pressure during Bevacizumab Therapy: The Prospective AVALUE Cohort Study. Oncology Research and Treatment, 2014, 37, 230-236.	1.2	14
1133	Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiology and Oncology, 2014, 48, 184-188.	1.7	6
1134	Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepatic Oncology, 2014, 1, 363-375.	4.2	2
1136	Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer, 2015, 15, 643.	2.6	23
1137	Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardio-Oncology, 2015, 1, 6.	1.7	25
1138	Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience. 2015. 9. 582.	1.1	7

#	Article	IF	CITATIONS
1139	Epoetin beta for the treatment of chemotherapy-induced anemia: an update. OncoTargets and Therapy, 2015, 8, 583.	2.0	5
1140	Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). OncoTargets and Therapy, 2015, 8, 1111.	2.0	10
1141	Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Management and Research, 2015, 7, 133.	1.9	84
1142	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. Clinical Interventions in Aging, 2015, 10, 127.	2.9	2
1143	An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab. International Journal of Biological Markers, 2015, 30, 73-80.	1.8	5
1144	Targeted Cancer Therapy: The Next Generation of Cancer Treatment. Current Drug Discovery Technologies, 2015, 12, 3-20.	1.2	429
1145	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Design, Development and Therapy, 2015, 9, 1653.	4.3	7
1146	Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World Journal of Gastroenterology, 2015, 21, 5072.	3.3	59
1147	Bleeding after Bevacizumab Treatment in Patients with Metastatic Colorectal Cancer. Tumori, 2015, 101, 46-51.	1.1	8
1148	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0136324.	2.5	25
1149	Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS ONE, 2015, 10, e0131095.	2.5	10
1150	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE, 2015, 10, e0135599.	2.5	22
1151	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International, 2015, 2015, 1-13.	1.9	59
1153	Maternal Preeclampsia and Bronchopulmonary Dysplasia. Korean Journal of Perinatology, 2015, 26, 167.	0.1	0
1154	Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Annals of Oncology, 2015, 26, 1201-1207.	1.2	134
1155	Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). European Journal of Cancer, 2015, 51, 935-941.	2.8	25
1156	Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. OncoTargets and Therapy, 2015, 8, 243.	2.0	1
1157	Two Cases of Acute Abdomen after an Intravitreal Injection of Bevacizumab. Case Reports in Ophthalmology, 2015, 6, 110-114.	0.7	8

		CITATION R	EPORT	
#	Article		IF	Citations
1158	Bevacizumab: A dose review. Critical Reviews in Oncology/Hematology, 2015, 94, 311-3	322.	4.4	32
1159	First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nature Re Oncology, 2015, 12, 607-619.	views Clinical	27.6	138
1160	Updates in Preeclampsia. Current Anesthesiology Reports, 2015, 5, 74-81.		2.0	1
1161	Bevacizumab increases the risk of infections in cancer patients: A systematic review and analysis of 41 randomized controlled trials. Critical Reviews in Oncology/Hematology, 2 323-336.	l pooled 015, 94,	4.4	24
1162	Proof of prometastatic niche induction by hepatic stellate cells. Journal of Surgical Rese 194, 496-504.	arch, 2015,	1.6	40
1163	Systemic Therapy for Patients with Colorectal Cancer: State of the Art. , 2015, , 109-13	2.		1
1164	Systems pharmacology approaches for optimization of antiangiogenic therapies: challe opportunities. Frontiers in Pharmacology, 2015, 6, 33.	nges and	3.5	13
1165	Five-year survival and costs of care in metastatic colorectal cancer: conventional versus antibody-based treatment protocols. Expert Review of Anticancer Therapy, 2015, 15, 96	monoclonal 53-970.	2.4	12
1166	Approach to chemotherapy-associated thrombosis. Vascular Medicine, 2015, 20, 153-1	61.	1.5	54
1167	Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a c review of literature. Japanese Journal of Clinical Oncology, 2015, 45, 286-290.	case report and	1.3	9
1168	Expression, Purification, and Therapeutic Implications of Recombinant sFRP1. Applied B Biotechnology, 2015, 175, 2087-2103.	ochemistry and	2.9	10
1169	FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE st Oncology, 2015, 26, 1427-1433.	cancer after udy. Annals of	1.2	45
1170	Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation inducing empty basement membrane sleeves in xenograft tumours. British Journal of Ca 495-503.	without ancer, 2015, 112,	6.4	29
1171	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treat colorectal cancer. International Journal of Clinical Oncology, 2015, 20, 207-239.	ment of	2.2	548
1173	A fresh look at zebrafish from the perspective of cancer research. Journal of Experiment Clinical Cancer Research, 2015, 34, 80.	al and	8.6	85
1174	Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?. Drug 1833-1842.	s, 2015, 75,	10.9	3
1175	Bevacizumab with chemotherapy in patients withKRASwild-type metastatic colorectal c registry data. Future Oncology, 2015, 11, 225-232.	ancer: Czech	2.4	2
1176	Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro 2015, 124, 501-506.	o-Oncology,	2.9	18

#	Article	IF	CITATIONS
1178	Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. Colorectal Cancer, 2015, 4, 13-25.	0.8	0
1180	Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression. Molecular Cancer Therapeutics, 2015, 14, 470-479.	4.1	24
1181	An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Targeted Oncology, 2015, 10, 55-63.	3.6	17
1182	Unravelling the theories of preâ€eclampsia: are the protective pathways the new paradigm?. British Journal of Pharmacology, 2015, 172, 1574-1586.	5.4	65
1183	Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study. Acta Oncológica, 2015, 54, 171-178.	1.8	14
1184	Pharmaceutical Biotechnology. , 0, , .		7
1185	Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. OncoTargets and Therapy, 2016, 9, 2421.	2.0	13
1186	Fibroblast Growth Factors and their Emerging Cancer-Related Aspects. Journal of Cancer Science & Therapy, 2016, 08, .	1.7	4
1187	Targeting angiogenesis in gastrointestinal tumors: current challenges. Translational Gastroenterology and Hepatology, 2016, 1, 67-67.	3.0	15
1188	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. BioMed Research International, 2016, 2016, 1-14.	1.9	19
1189	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointestinal Cancer: Targets and Therapy, 2016, Volume 6, 21-30.	5.5	8
1190	Nanoencapsulation of green tea catechins and its efficacy. , 2016, , 555-586.		0
1192	Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS ONE, 2016, 11, e0161912.	2.5	31
1193	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Supportive Care in Cancer, 2016, 24, 4057-4074.	2.2	21
1194	Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain. Medicine (United) Tj ETQq0 0	0 [gBT /O	verlock 10 Tf
1195	Preoperative Assessment of Colorectal Patients. , 2016, , 93-106.		0
1196	Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (AgedÂ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral) Tj ETQq0 0 0 r 236-242	gBT /Over	ock 10 Tf 50
1197	Analysis of Clinical End Points of Randomised Trials Including Bevacizumab and Chemotherapy versus Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer. Clinical Oncology, 2016, 28, e155-e164.	1.4	9

#	Article	IF	CITATIONS
1198	Effect of recombinant human endostatin onradiotherapy for esophagus cancer. Asian Pacific Journal of Tropical Medicine, 2016, 9, 86-90.	0.8	9
1199	The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. Journal of the Royal College of Surgeons of Edinburgh, 2016, 14, 327-336.	1.8	27
1200	Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. Journal of Gastrointestinal Cancer, 2016, 47, 264-272.	1.3	2
1201	Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis. Tumor Biology, 2016, 37, 14341-14354.	1.8	23
1203	Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer, 2016, 16, 677.	2.6	86
1204	Targeted nanoparticles for colorectal cancer. Nanomedicine, 2016, 11, 2443-2456.	3.3	117
1205	Targeted Therapy of Colorectal Cancer. Oncology Research and Treatment, 2016, 39, 796-802.	1.2	38
1207	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	2.3	10
1208	Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chinese Journal of Cancer, 2016, 35, 61.	4.9	32
1209	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
1210	Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. Medicine (United States), 2016, 95, e4232.	1.0	16
1211	Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clinical Sarcoma Research, 2016, 6, 9.	2.3	10
1212	Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Medicine (United States), 2016, 95, e5221.	1.0	5
1213	Managing the Primary Tumor with Unresectable Synchronous Colorectal Metastases. Current Colorectal Cancer Reports, 2016, 12, 170-179.	0.5	0
1214	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clinical Pharmacokinetics, 2016, 55, 1381-1394.	3.5	46
1215	Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. Gastroenterology, 2016, 151, 427-439.e6.	1.3	117
1216	Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemotherapy and Pharmacology, 2016, 78, 341-351.	2.3	52
1217	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	3.2	72

щ		15	CITATIONS
#	Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surgical	IF	CHATIONS
1218	Oncology, 2016, 25, 190-199.	1.6	12
1220	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	46.4	724
1221	The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?. Journal of Neuro-Oncology, 2016, 127, 493-502.	2.9	21
1222	Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials. Tumor Biology, 2016, 37, 6297-6306.	1.8	0
1223	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0
1224	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. Hellenic Journal of Cardiology, 2017, 58, 215-219.	1.0	17
1225	Chemotherapy in Old Women with Breast Cancer: Is Age Still a Predictor for Under Treatment?. Breast Journal, 2017, 23, 256-266.	1.0	19
1226	A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. British Journal of Cancer, 2017, 116, 600-608.	6.4	25
1227	Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Trends in Molecular Medicine, 2017, 23, 282-292.	6.7	70
1228	Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin. Nanotechnology, 2017, 28, 075102.	2.6	19
1229	Second-line systemic therapy for metastatic colorectal cancer. The Cochrane Library, 2017, 1, CD006875.	2.8	26
1230	Cardio-Oncology. , 2017, , .		1
1232	Vascular Complications of Cancer and Cancer Therapy. , 2017, , 215-240.		0
1234	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2017, , 1-16.		Ο
1235	Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre. Scandinavian Journal of Gastroenterology, 2017, 52, 1-7.	1.5	7
1236	Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. European Journal of Surgical Oncology, 2017, 43, 1668-1681.	1.0	45
1237	Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. Seminars in Interventional Radiology, 2017, 34, 145-166.	0.8	18
1238	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. Angiogenesis, 2017, 20, 185-204.	7.2	482

		ITATION REF	PORT	
#	ARTICLE Phase II study of the Multibinase inhibitor of angiogenesis Linifanib, in patients with metastatic and		IF	CITATIONS
1239	refractory colorectal cancer expressing mutated KRAS. Investigational New Drugs, 2017, 35, 491-49	8.	2.6	7
1241	Receptor Tyrosine Kinases as Targets for Enhancing Tumor Radiosensitivity. Cancer Drug Discovery and Development, 2017, , 35-55.		0.4	1
1242	Preeclampsia: A Mirror into Future Cardiovascular and Renal Health. , 2017, , 385-393.			0
1243	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics, 2017, 37, 1371-1387.		3.3	56
1244	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.		4.4	13
1245	Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Metaâ€Analys More Than 20Â000 Patients. Journal of the American Heart Association, 2017, 6, .	is of	3.7	125
1246	Proper oral hygiene protocols decreased inflammation of gingivitis in a patient during chemotherapy with bevacizumab: a case report. Clinical Case Reports (discontinued), 2017, 5, 1352-1357.	/	0.5	2
1247	Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 2017, 12, 599-610.		3.6	121
1248	Tumor angiogenesis revisited: Regulators and clinical implications. Medicinal Research Reviews, 201 37, 1231-1274.	7,	10.5	138
1249	Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study. Scientific Reports, 2017, 7, 2911.		3.3	30
1250	Pathophysiology of hypertension in preeclampsia. Microvascular Research, 2017, 109, 34-37.		2.5	27
1251	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.			0
1252	Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e253-e261.		1.1	4
1253	Biomaterialâ€Based Implantable Devices for Cancer Therapy. Advanced Healthcare Materials, 2017, 1600766.	6,	7.6	83
1255	Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. Hamostaseologie, 2017, 37, 241-255.		1.9	12
1256	Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer. Journal of Thoracic Disease, 2017, 9, 1891-1902.		1.4	6
1258	The Role of Angiogenesis in Cancer Treatment. Biomedicines, 2017, 5, 34.		3.2	419
1259	Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Meta Cancer Patients: A Pilot Study. International Journal of Molecular Sciences, 2017, 18, 1458.	static	4.1	14

#	Article	IF	CITATIONS
1260	Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics, 2017, 7, 400-412.	10.0	71
1261	Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Computational Biology, 2017, 13, e1005724.	3.2	38
1262	Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer. Kosin Medical Journal, 2017, 32, 170.	0.3	0
1263	Hypertension and Cancer. , 2017, , 249-255.		0
1264	Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Medicine and Pharmacy Reports, 2017, 90, 377-384.	0.4	3
1265	The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget, 2017, 8, 73009-73016.	1.8	29
1266	Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. Neuro-Oncology Practice, 2017, 4, 24-28.	1.6	4
1267	Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 325-340.	27.6	1,192
1268	Does the tumour microenvironment alter tumorigenesis and clinical response in transmissible venereal tumour in dogs?. Veterinary and Comparative Oncology, 2018, 16, 370-378.	1.8	10
1270	Placental growth factor: A review of literature and future applications. Pregnancy Hypertension, 2018, 14, 260-264.	1.4	12
1271	Should Biological Targeted Agents be Combined with Preoperative Chemoradiation in Rectal Cancer? An Update. , 2018, , 273-285.		0
1272	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	2.4	41
1273	Efficacy for lung metastasis induced by the allogeneic bEnd3 vaccine in mice. Human Vaccines and Immunotherapeutics, 2018, 14, 1294-1304.	3.3	2
1274	Surgery for Recurrent High-Grade Clioma After Treatment with Bevacizumab. World Neurosurgery, 2018, 110, e727-e737.	1.3	14
1277	Novel Therapies for Preeclampsia. Comprehensive Gynecology and Obstetrics, 2018, , 227-237.	0.0	0
1278	Preeclampsia. Comprehensive Gynecology and Obstetrics, 2018, , .	0.0	6
1279	Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integrative Cancer Therapies, 2018, 17, 41-51.	2.0	16
1280	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 1-34.	2.2	1,187

#	Article	IF	CITATIONS
1281	Immunotherapy regimens for metastatic colorectal carcinomas. Human Vaccines and Immunotherapeutics, 2018, 14, 250-254.	3.3	14
1282	Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. Journal of Geriatric Oncology, 2018, 9, 15-23.	1.0	31
1283	Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network metaâ€analysis. Journal of Cellular Biochemistry, 2018, 119, 1521-1537.	2.6	5
1284	Antiangiogenic Therapy in Colorectal Cancer. Cancer Journal (Sudbury, Mass ), 2018, 24, 165-170.	2.0	77
1286	Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. OncoTargets and Therapy, 2018, Volume 11, 8605-8621.	2.0	14
1287	Risk factors for thrombosis risk in patients with cancer. Journal of Oncological Science, 2018, 4, 130-133.	0.1	3
1288	Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties. Scientific Reports, 2018, 8, 17361.	3.3	12
1289	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 845-855.	8.1	32
1290	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
1291	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. , 2018, , 115-140.		0
1293	Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. OncoTargets and Therapy, 2018, Volume 11, 5059-5074.	2.0	23
1294	Novel Therapeutic Strategies for Solid Tumor Based on Body's Intrinsic Antitumor Immune System. Cellular Physiology and Biochemistry, 2018, 47, 441-457.	1.6	11
1295	Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. British Journal of Cancer, 2018, 119, 164-169.	6.4	22
1296	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
1297	Tyrosine Kinase Inhibitor-Induced Hypertension. Current Oncology Reports, 2018, 20, 65.	4.0	61
1298	Cardiotoxicity. , 2018, , 367-406.		4
1299	Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. Journal of Medical Case Reports, 2018, 12, 84.	0.8	13
1300	Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. Frontiers in Physiology, 2018, 9, 973.	2.8	131

#		IF	CITATIONS
1301	rectal adenocarcinoma in patients receiving total mesorectal excision. Journal of Cancer, 2018, 9, 950-958.	2.5	7
1302	Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. American Journal of Gastroenterology, 2018, 113, 1836-1847.	0.4	17
1303	Pro―and antiangiogenic therapies: current status and clinical implications. FASEB Journal, 2019, 33, 34-48.	0.5	56
1304	Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treatment and Research, 2019, 179, 87-101.	0.5	45
1305	Operative and periâ€operative considerations in the management of brain metastasis. Cancer Medicine, 2019, 8, 6809-6831.	2.8	28
1306	Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 1052.	3.5	3
1307	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release, 2019, 307, 108-138.	9.9	49
1308	Analysis of Anti–Vascular Endothelial Growth Factor Injection Claims Data in US Medicare Part B Beneficiaries From 2012 to 2015. JAMA Ophthalmology, 2019, 137, 921.	2.5	27
1309	Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Reports, 2019, 12, e228612.	0.5	3
1310	How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?. BMC Systems Biology, 2019, 13, 30.	3.0	17
1312	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Seminars in Cancer Biology, 2019, 59, 3-22.	9.6	29
1313	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. Journal of Surgical Oncology, 2019, 119, 564-582.	1.7	55
1314	Targeting Angiogenesis by Blocking the ATM–SerRS–VEGFA Pathway for UV-Induced Skin Photodamage and Melanoma Growth. Cancers, 2019, 11, 1847.	3.7	12
1315	Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10Âyear duration. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 1225-1234.	2.4	24
1316	Sildenafil for the treatment of preeclampsia, an update: should we still be enthusiastic?. Nephrology Dialysis Transplantation, 2019, 34, 1819-1826.	0.7	15
1317	Diagnosis and Surgical Management of Renal Tumors. , 2019, , .		1
1318	Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. European Journal of Cancer, 2019, 106, 37-44.	2.8	44
1319	Dynamic platelet function is markedly different in patients with cancer compared to healthy donors. Platelets, 2019, 30, 737-742.	2.3	4

#	Article	IF	CITATIONS
1320	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1-42.	2.2	1,123
1321	The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Oncologist, 2020, 25, e451-e459.	3.7	30
1322	Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers, 2020, 12, 111.	3.7	31
1323	Harnessing an Artificial Intelligence Platform to Dynamically Individualize Combination Therapy for Treating Colorectal Carcinoma in a Rat Model. Advanced Therapeutics, 2020, 3, 1900127.	3.2	7
1325	Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. Melanoma Research, 2020, 30, 102-106.	1.2	6
1326	Tumor Therapeutic Modes. , 2020, , 135-229.		1
1327	Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial. Journal of Clinical Medicine, 2020, 9, 3130.	2.4	11
1328	MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. Clinical Colorectal Cancer, 2020, 19, 311-318.e1.	2.3	4
1329	Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. Frontiers in Oncology, 2020, 10, 590707.	2.8	14
1330	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. Journal of Clinical Medicine, 2020, 9, 3889.	2.4	35
1331	Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen–Deuterium Exchange Mass Spectrometry. Biochemistry, 2020, 59, 2776-2781.	2.5	11
1332	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. Thrombosis Research, 2020, 191, S79-S84.	1.7	22
1333	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thrombosis Research, 2020, 191, S3-S11.	1.7	26
1334	Effect of Chitosan Magnetic Nanoparticles Loaded with Ang2-siRNA Plasmids on the Growth of Melanoma Xenografts in Nude Mice. Cancer Management and Research, 2020, Volume 12, 7475-7485.	1.9	12
1335	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. Clinical Colorectal Cancer, 2020, 19, e140-e150.	2.3	9
1336	Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. Journal of Cancer, 2020, 11, 4474-4494.	2.5	128
1337	Clinical and Economic Impact of Tailoring Screening to Predicted Colorectal Cancer Risk: A Decision Analytic Modeling Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 318-328.	2.5	12
1338	Administration sequence for multi-agent oncolytic regimens. Journal of Oncology Pharmacy Practice, 2020, 26, 933-942.	0.9	1

#	Article	IF	CITATIONS
1339	Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naÃīve older or frail patients with metastatic colorectal cancer (OGSC 0802). International Journal of Clinical Oncology, 2020, 25, 1291-1298.	2.2	5
1340	Bevacizumab (Avastin®) in cancer treatment: A review of 15Âyears of clinical experience and future outlook. Cancer Treatment Reviews, 2020, 86, 102017.	7.7	573
1341	Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 2976-2980.	2.4	1
1342	Antiâ€VEGF DNAâ€based aptamers in cancer therapeutics and diagnostics. Medicinal Research Reviews, 2021, 41, 464-506.	10.5	39
1343	Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden. Journal of Proteomics, 2021, 231, 104015.	2.4	9
1344	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. International Journal of Clinical Oncology, 2021, 26, 598-605.	2.2	6
1345	Recent Advances in Molecular Imaging of Colorectal Tumors. Digestion, 2021, 102, 57-64.	2.3	7
1346	A History of Anti-VEGF Inhibitors in the Ophthalmic Literature: A Bibliographic Review. Journal of Vitreoretinal Diseases, 2021, 5, 304-312.	0.7	0
1347	VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive Bâ€cell lymphoma. European Journal of Haematology, 2021, 106, 100-104.	2.2	4
1348	Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. Laryngoscope, 2021, 131, E921-E928.	2.0	11
1349	Therapy targeting angiogenic potential of tumor. , 2021, , 113-139.		0
1350	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy and Practice, 2021, 6, 238146832110210.	0.9	10
1351	Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies. International Journal of Molecular Sciences, 2021, 22, 520.	4.1	17
1352	Optimal duration of therapy in the first line treatment of metastatic colorectal cancer: Single center experience. Vojnosanitetski Pregled, 2022, 79, 796-804.	0.2	2
1353	Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis. Advances in Experimental Medicine and Biology, 2021, 1306, 81-99.	1.6	2
1354	Targeted Drug Delivery in Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 356-381.	0.1	0
1355	Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell International, 2021, 21, 83.	4.1	17
1356	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers, 2021, 13, 1374.	3.7	18

CITATION REPORT ARTICLE IF CITATIONS Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Frontiers in Oncology, 2021, 11, 2.8 9 628138. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers, 2021, 13, 1031. 3.7 Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National 4.9 758 Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokineticsÂand future 2.4 treatment strategies. Future Oncology, 2021, 17, 2243-2256. Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer 1.2 4 (mCRC) Patients in Indonesia. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1921-1926. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Journal of Oncology, 2021, 2021, 1-17. 1.3 Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal 4.2 2 liver metastases. Hepatic Oncology, 2022, 9, HEP40. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. Journal of Chemotherapy, 2022, 34, 1.5 221-234. Precision medicine: Uses and challenges. Medical Journal Armed Forces India, 2021, 77, 258-265. 0.8 14 Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian 1.4 Provinces. Clinical Oncology, 2022, 34, e7-e17. The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. 4 3.5 Frontiers in Pharmacology, 2020, 11, 625498. Obtacles and opportunities in the clinical development of targeted therapeutics., 2005, 63, 19-41. Angiogenesis inhibitors: What is the clinical future?., 2005, 63, 67-91. 1 The Clinical Utility of Bevacizumab., 2008, , 375-385. Chemotherapy-Associated Thrombosis. Cancer Treatment and Research, 2009, 148, 181-206. 0.58 The Coagulation System and Angiogenesis. Cancer Treatment and Research, 2009, 148, 67-80.

Anticancer drugs. , 2008, , 511-535.
Vascular Endothelial Growth Factor Inhibitors in Colon Cancer. Advances in Experimental Medicine

2

72

and Biology, 2006, 587, 251-275.

1357

1359

1360

1361

1363

1364

1365

1367

1369

1370

1371
	CITATION	Report	
#	Article	IF	CITATIONS
1376	Monoclonal Antibodies in Cancer Therapy. , 2007, , 453-484.		1
1378	Targeted Therapy in Colorectal Cancer. , 2008, , 101-123.		2
1379	Therapeutic Human Monoclonal Antibodies Against Cancer. Methods in Molecular Biology, 2014, 1060, 61-77.	0.9	20
1380	Biology of Colorectal Cancer Liver Metastases. , 2009, , 1-10.		1
1381	Aging Disorders of the Eye: Challenges and Approaches for Their Treatment. , 2016, , 277-320.		1
1382	Tyrosine Kinase Inhibitors and Cancer Therapy. , 2007, 172, 25-44.		5
1383	Monoclonal antibody therapy. , 2009, , 303-406.		4
1385	Management of diarrhea. , 2006, , 1165-1176.		1
1387	Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4258s-4262s.	7.0	103
1388	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	1.8	7
1389	Early Detection of Tumor Vascular Response to Anti-Angiogenic Drugs with Optical Tomography. , 2010, , .		1
1390	Dynamic Fluorescence Imaging For The Detection of Vascular Changes in Anti-Angiogenic Drug Therapy. , 2010, , .		2
1391	Targeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics. PLoS ONE, 2009, 4, e5233.	2.5	105
1392	The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review. PLoS ONE, 2013, 8, e51780.	2.5	72
1393	Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis. PLoS ONE, 2013, 8, e66721.	2.5	54
1394	An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients. PLoS ONE, 2014, 9, e89960.	2.5	27
1395	Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. PLoS ONE, 2014, 9, e102484.	2.5	70
1396	Bevacizumab induced intestinal perforation in patients with colorectal cancer. Korean Journal of Clinical Oncology, 2019, 15, 15-18.	0.1	4

#	Article	IF	CITATIONS
1397	Estimation of Serum Levels of VEGF & SVEGFR-1 (sFLT-1) in Preeclampsia. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 913-918.	0.1	2
1399	Antibody-based antiangiogenic and antilymphangiogenic therapies to prevent tumor growth and progression Acta Biochimica Polonica, 2013, 60, .	0.5	8
1400	Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience, 2014, 1, 540-549.	2.2	22
1401	Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. Oncotarget, 2017, 8, 36707-36715.	1.8	4
1402	Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget, 2017, 8, 51492-51506.	1.8	38
1403	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-529.	1.8	12
1404	Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. Oncotarget, 2018, 9, 10536-10548.	1.8	8
1405	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget, 2016, 7, 46678-46691.	1.8	35
1406	Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy. Current Drug Targets, 2010, 11, 1000-1017.	2.1	318
1407	Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect. Current Gene Therapy, 2015, 15, 228-244.	2.0	25
1408	The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs. Current Vascular Pharmacology, 2011, 9, 358-380.	1.7	24
1409	1,3,5-Triazine Analogs: A Potent Anticancer Scaffold. Current Signal Transduction Therapy, 2019, 14, 87-106.	0.5	8
1410	Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence – A Phase II Study. Anticancer Research, 2017, 37, 2683-2691.	1.1	10
1411	Role of lymphangiogenesis in lung cancer Folia Histochemica Et Cytobiologica, 2010, 47, 333-42.	1.5	12
1412	Placental cytokines and preeclampsia. Frontiers in Bioscience - Landmark, 2007, 12, 2706.	3.0	50
1413	Expression of Placenta Growth Factor in Colorectal Carcinomas. Journal of the Korean Society of Coloproctology, 2012, 28, 315.	0.9	15
1414	Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology, 2007, 14, 13-20.	2.2	124
1415	Cancer-Associated Thrombosis: Prevention and Treatment. Current Oncology, 2008, 15, 58-67.	2.2	51

#	Article	IF	Citations
1416	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World Journal of Gastroenterology, 2009, 15, 449.	3.3	34
1417	Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding. World Journal of Gastroenterology, 2007, 13, 5979.	3.3	57
1418	Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells. World Journal of Gastroenterology, 2007, 13, 2044.	3.3	4
1419	Metastatic colorectal cancer-past, progress and future. World Journal of Gastroenterology, 2007, 13, 3806.	3.3	64
1420	Exploiting novel molecular targets in gastrointestinal cancers. World Journal of Gastroenterology, 2007, 13, 5845.	3.3	16
1421	New approaches in angiogenic targeting for colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5857.	3.3	50
1422	Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5867.	3.3	26
1423	Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World Journal of Gastroenterology, 2007, 13, 6231.	3.3	18
1424	Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World Journal of Gastroenterology, 2011, 17, 4867.	3.3	12
1425	Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World Journal of Gastroenterology, 2012, 18, 1104.	3.3	6
1426	Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World Journal of Gastroenterology, 2012, 18, 541.	3.3	29
1427	Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives. World Journal of Gastroenterology, 2013, 19, 7955.	3.3	30
1428	Immunotherapy in human colorectal cancer: Challenges and prospective. World Journal of Gastroenterology, 2016, 22, 6362.	3.3	41
1429	Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Chinese Medical Journal, 2014, 127, 538-546.	2.3	1
1431	Intravitreal Bevacizumab in a Patient With Neovascular Glaucoma. Ophthalmic Surgery Lasers and Imaging Retina, 2006, 37, 144-146.	0.7	120
1432	Needle Bleb Revision of Encapsulated Filtering Bleb With Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2006, 37, 148-150.	0.7	87
1433	Macular Infarction Following Intravitreal Bevacizumab for Treatment of Central Retinal Vein Occlusion. Ophthalmic Surgery Lasers and Imaging Retina, 2012, 43, e73-9.	0.7	8
1434	Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. Indian Journal of Medical Research, 2016, 143, 145.	1.0	13

#	Article	IF	CITATIONS
1435	Antiangiogenic mechanisms and factors in breast cancer treatment. Journal of Carcinogenesis, 2016, 15, 1.	2.5	39
1436	Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin®). Cancer Research and Treatment, 2008, 40, 33.	3.0	23
1437	Recent Advances in the Management of Stage IV Colon Cancer. Journal of Cancer Therapy, 2012, 03, 1104-1118.	0.4	5
1438	Anti-angiogenic agents in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 71.	2.0	22
1439	Novel therapeutic agents in the treatment of metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 99.	2.0	22
1440	Colorectal hepatic metastasis: Evolving therapies. World Journal of Hepatology, 2014, 6, 453.	2.0	11
1441	Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. ISRN Ophthalmology, 2011, 2011, 1-4.	1.7	2
1442	A Case of a Bevacizumab-Associated Penetration into the Mesocolon, undergoing Right Colectomy with Primary Anastomosis. Japanese Journal of Gastroenterological Surgery, 2009, 42, 1528-1533.	0.1	2
1443	Pro-Angiogenic Mediators as Targets for Chemotherapy of Colorectal Carcinoma. American Journal of Medicine and Medical Sciences, 2012, 1, 7-14.	1.0	1
1444	Anti-VEGF Therapy with Bevacizumab - Limited Cardiovascular Toxicity. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10769-10772.	1.2	3
1445	Predictive Significance of VEGF and HIF-11̂± Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6149-6154.	1.2	16
1446	Characterization of Anti-Angiogenic Chemo-Sensitization via Longitudinal Ultrasound Localization Microscopy in Colorectal Carcinoma Tumor Xenografts. IEEE Transactions on Biomedical Engineering, 2022, 69, 1449-1460.	4.2	8
1447	Knockdown of PPARδ Induces VEGFA-Mediated Angiogenesis via Interaction With ERO1A in Human Colorectal Cancer. Frontiers in Oncology, 2021, 11, 713892.	2.8	3
1448	Therapeutic effects of green tea on endometriosis. Critical Reviews in Food Science and Nutrition, 2023, 63, 3222-3235.	10.3	5
1449	VEGF and Its Receptors. , 2004, , 1-11.		0
1450	VEGF in Colorectal Cancer. , 2004, , 64-71.		0
1451	Trends in the Treatment of Colorectal Cancer. Oncology & Hematology Review, 2005, 00, 1.	0.2	0
1452	Cancers of the large bowel and hepatobiliary tract. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 443-469.	0.5	0

	Ci	tation Repo	ORT	
#	Article		IF	CITATIONS
1453	Tumor Angiogenesis: General Principles and Therapeutic Approaches. , 2005, , 41-55.			0
1454	New Advances in the Chemotherapy of Metastatic Colorectal Cancer. Oncology & Hematology Review 2006, 00, 1.	ν,	0.2	0
1455	Inhibition der Tumorangiogenese und Neoangiogenese. , 2006, , 767-775.			0
1456	Kolorektales Karzinom. , 2006, , 3787-3937.			1
1458	Blockade Of Endogenous Vascular Endothelial Growth Factor (VEGF) Reveals A Role For Endothelium In The Regulation Of Mammalian Glomerular Permeability. FASEB Journal, 2006, 20, A763.	r	0.5	0
1460	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020 Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, .	), in	2.7	0
1462	5. 囲形癌é~域. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 393-400	).	0.1	0
1463	Chemotherapy of Liver Tumors. , 2007, , 1298-1311.			0
1464	The Role of Targeted Therapy in the Treatment of Metastatic Colorectal Cancer. Journal of the Korean Society of Coloproctology, 2007, 23, 524.	ſ	0.2	1
1466	Antiangiogenetic drugs—mechanisms of action. , 2007, , 339-346.			0
1467	Pharmacodynamic Markers in Tissues. , 2007, , 515-534.			0
1468	Pharmacodynamic Markers in Tissues. , 2007, , .			0
1469	SURVEILLANCE AND TREATMENT OF RECURRENCE IN COLORECTAL CANCER. , 2008, , 1263-1300.			0
1470	MANAGEMENT OF CARCINOMA OF THE COLON. , 2008, , 1047-1114.			1
1472	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-36	55.		0
1474	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Diseas , 2008, , 63-80.	se.		1
1475	Phase 1 Trials Today. , 2008, , 553-570.			0
1476	Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. , 2008, , 401-422.			0

		CHAHON K	LPORT	
#	ARTICLE Venous Thromboembolism and Anticoagulation, Translational Medicine Series, 2008. , 1-2	9.	IF 0.0	CITATION
1479	Pathogenesis and Management of Venous Thromboembolism in Cancer Patients. , 2009, ,	. 109-137.		0
1481	Surgery for Colorectal Metastases. , 2009, , 1-14.			2
1483	Progress in the treatment of colorectal cancer: the impact of new drugs. , 2009, , 176-190	).		0
1484	Targeted Approaches to Drug Development. , 2009, , 57-98.			3
1485	Biological therapy of colon cancer. , 2009, , 659-668.			0
1486	Monoclonal Antibody Therapy for Hematologic Malignancies. , 2010, , 493-536.			0
1487	Chemotherapy Trials for Colorectal Cancer in Advanced Disease: What's the Current H 2010, , 27-54.	lypothesis?. ,		0
1488	Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-24	1.		0
1490	Challenges and Successes in Developing Effective Anti-angiogenic Agents. , 2011, , 347-4	01.		0
1491	Inhibitors of Tumor Angiogenesis. , 2011, , 331-340.			0
1493	Risk of Thromboembolism with the Angiogenesis inhibitor Bevacizumab in Metastatic Col Cancer Patients. Journal of Korean Society of Health-System Pharmacists, 2011, 28, 1-9.	p-Rectal	0.1	0
1494	Leucovorin, Fluorouracil, and Irinotecan (FOLFIRI) plus Bevacizumab for Metastatic Colore Cancer. Hospital Pharmacy, 2011, 46, 748-754.	ctal	1.0	1
1497	Green Tea for Endometriosis. , 0, , .			0
1498	Hypertension and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab. Journal of Korean Society of Health-System Pharmacists, 2012, 29, 324-337	,	0.1	1
1499	Oxidative Stress and Angiogenesis in Tumor Progression. , 2013, , 394-425.			0
1500	Role of TRPC and Orai Channels in Vascular Remodeling. , 2014, , 463-490.			0
1502	Acute Abdomen, Bowel/Biliary Obstruction, and Fistula. , 2014, , 694-704.			0

#	Article	IF	CITATIONS
1503	Venous Thromboembolism among Cancer Patients:A Review. , 2014, 21, .		0
1504	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients. , 2014, , 135-142.		0
1505	Mechanisms of Cardiac Dysfunction Associated with Cancer Therapeutics. , 2012, , 291-316.		0
1506	BEVACIZUMAB COMBINED WITH IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN AS THE FIRST- LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA. Journal of IMAB, 2014, 20, 556-559.	0.1	0
1507	Phase I Trials Today. , 2015, , 661-676.e2.		0
1508	A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer. Journal of Cancer Therapy, 2015, 06, 153-162.	0.4	0
1509	Chemotherapy Induced Cardiomyopathy. , 2015, , 199-211.		0
1511	Pathophysiology of Hypertension in Preeclampsia. Clinical Practice (London, England), 2016, 13, .	0.1	2
1512	Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digital Journal of Ophthalmology: DJO, 2015, 21, 29-34.	0.6	7
1513	A Case of Intestinal Perforation during Bevacizumab Combination Chemotherapy for Inoperable Advanced Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 2910-2914.	0.0	0
1514	FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES. Journal of IMAB, 2016, 22, 1039-1044.	0.1	0
1515	Hyperthermic Intraperitoneal Chemotherapy. Gl Surgery Annual, 2017, , 177-195.	0.0	Ο
1517	The Role of the Neuropilins in Tumour Angiogenesis and Tumour Progression. , 2017, , 163-186.		0
1518	Cutaneous Reactions to Targeted Anticancer Agents. , 2018, , 139-153.		0
1519	CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES. Meditsinskiy Sovet, 2017, , 67-76.	0.5	2
1520	On Design and Analysis of Dose-Response Trials for Early Clinical Development. ICSA Book Series in Statistics, 2018, , 377-403.	0.2	0
1521	Efferent therapy in the first-line drug treatment of metastatic colorectal cancer. Meditsinskiy Sovet, 2018, , 172-175.	0.5	0
1522	Cardiovascular Damage in Clinical Trials. Current Clinical Pathology. 2019 205-217.	0.0	0

#	Article	IF	Citations
1523	Pre-surgical Treatment of Renal Cell Carcinoma. , 2019, , 247-262.		0
1524	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		Ο
1525	Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2019, , 379-394.		0
1526	An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. Translational Cancer Research, 2019, 8, 2357-2370.	1.0	1
1528	Gastrointestinal Complications of Chemotherapy. , 2020, , 29-50.		0
1529	Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. Iranian Red Crescent Medical Journal, 2020, 22, .	0.5	2
1530	A roadmap for medical treatment of metastatic CRC. , 2022, , 365-379.		0
1532	Therapy Regimens Used in Adjuvant and Neoadjuvant Treatment of the Discussed Tumor Types. , 2005, , 503-551.		0
1533	Molekulare Prognosemarker des Harnblasenkarzinoms. , 2005, , 27-65.		0
1538	Antiangiogenesis Agents in Colorectal Cancer. , 2008, , 371-384.		0
1540	Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment. , 2007, , 85-98.		1
1544	The Development of Avastin. , 2008, , 611-653.		0
1545	The future in advanced prostate cancer: take your partners or is the last dance for me?. Reviews in Urology, 2004, 6 Suppl 10, S29-44.	0.9	1
1546	Individualization of therapy for colorectal cancer based on clinical and molecular parameters. Gastrointestinal Cancer Research: GCR, 2008, 2, S38-41.	0.7	3
1547	Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, S22-8.	0.7	0
1548	Targeted therapy in rectal cancer. Oncology, 2007, 21, 1055-65; discussion 1065, 1070, 1075 passim.	0.5	16
1549	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, 3, 429-41.	3.2	3
1550	Salivary protein factors are elevated in breast cancer patients. Molecular Medicine Reports, 2008, 1, 375-8.	2.4	48

#	Article	IF	CITATIONS
1552	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. OncoTargets and Therapy, 2009, 2, 1-15.	2.0	9
1553	Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. International Journal of Oncology, 2009, 34, 401-7.	3.3	14
1554	Translational research: current status, challenges and future strategies. American Journal of Translational Research (discontinued), 2011, 3, 422-33.	0.0	12
1555	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-29.	1.8	9
1556	Bevacizumab and intraocular tumors: an intriguing paradox. Molecular Vision, 2012, 18, 2454-67.	1.1	23
1558	Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. Hippokratia, 2012, 16, 196-9.	0.3	18
1559	Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2013, 111, 56-69.	1.4	10
1560	The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VECF through VEGFR1. Molecular Vision, 2014, 20, 649-60.	1.1	7
1561	Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. International Journal of Clinical and Experimental Medicine, 2015, 8, 1434-45.	1.3	10
1562	Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. American Health and Drug Benefits, 2016, 9, 221-32.	0.5	19
1563	Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. European Journal of Gynaecological Oncology (discontinued), 2013, 34, 113-9.	0.2	1
1565	Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. American Journal of Neuroradiology, 2006, 27, 409-17.	2.4	94
1567	Bevacizumab and Sinus Venous Thrombosis: A Literature Review. Cureus, 2021, 13, e19471.	0.5	1
1568	Chinese consensus on prevention of colorectal neoplasia (2021, <scp>S</scp> hanghai). Journal of Digestive Diseases, 2022, 23, 58-90.	1.5	7
1569	Discovery and Development of the Quininib Series of Ocular Drugs. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 33-42.	1.4	0
1570	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer. JAMA Oncology, 2022, 8, 537.	7.1	11
1571	Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A <scp>SEERâ€Medicare</scp> analysis. Cancer Medicine, 2022, 11, 1817-1826.	2.8	6
1572	Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107). Gastrointestinal Tumors, 2022, 9, 27-36.	0.7	0

			_
#	ARTICLE A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy	IF	CITATIONS
1573	in Patients with Metastatic Colorectal Cancer in Lebanon. Biologics: Targets and Therapy, 2022, Volume 16, 7-15.	3.2	0
1574	Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis. BMC Cancer, 2022, 22, 176.	2.6	2
1575	Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro. International Journal of Nephrology, 2021, 2021, 1-8.	1.3	4
1576	Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy. International Journal of Molecular Sciences, 2022, 23, 350.	4.1	2
1578	Antiangiogenic Agents for Liver Tumors. , 0, , 400-413.		0
1579	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2004, 9, 91-104.	2.4	1
1583	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	329.8	167
1584	Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. Frontiers in Oncology, 0, 12, .	2.8	4
1585	Overall Survival and Progression-Free Survival Comparison of Bevacizumab Plus Chemotherapy Combination Regiment versus Chemotherapy Only Regiment in Previously Untreated Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 269-277.	0.2	0
1586	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. Frontiers in Immunology, 0, 13, .	4.8	1
1587	Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Molecular Cancer Therapeutics, 2004, 3, 499-511.	4.1	79
1588	Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model. Clinical Cancer Research, 2005, 11, 407-409.	7.0	12
1589	Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study. Oncology Research and Treatment, 2022, 45, 576-587.	1.2	2
1590	PRIDE complex-like skin rash associated with bevacizumab. BMJ Case Reports, 2022, 15, e249844.	0.5	2
1591	New Frontiers in Translational Research in Neuro-oncology and the Blood-Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption Consortium Meeting. Clinical Cancer Research, 2005, 11, 421-428.	7.0	42
1592	Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, 2022, ,	0.9	0
1593	Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nature Reviews Clinical Oncology, 2022, 19, 681-697.	27.6	26
1595	Targeting the tumor stroma for cancer therapy. Molecular Cancer, 2022, 21, .	19.2	71

#	Article	IF	CITATIONS
1597	Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299.		0
1598	Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer. Cancers, 2023, 15, 9.	3.7	1
1599	Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Lithuania), 2023, 59, 350.	2.0	3
1600	A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX. ImmunoTargets and Therapy, 0, Volume 12, 17-23.	5.8	0
1601	Molecular basis and clinical application of targeted therapy in oncology. Medical Journal Armed Forces India, 2023, 79, 128-135.	0.8	3
1602	SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation. Future Oncology, 0, , .	2.4	0
1603	Pathophysiology of Gastrointestinal Tract Cancers and Therapeutic Status. , 2023, , 1-32.		0
1604	Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis. International Journal of Colorectal Disease, 2023, 38, .	2.2	0
1605	Metastasis in neuroblastoma: the MYCN question. Frontiers in Oncology, 0, 13, .	2.8	2
1606	Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer. Cancers, 2023, 15, 4564.	3.7	0
1608	Translational research of new developments in targeted therapy of colorectal cancer. Pathology Research and Practice, 2023, 252, 154888.	2.3	1
1609	Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada. Clinical Colorectal Cancer, 2024, 23, 46-57.e4.	2.3	0
1610	Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and <scp>metaâ€analysis</scp> . Cancer Medicine, 2023, 12, 21579-21591.	2.8	0
1611	Risk Factors and Pathophysiology of Venous Thromboembolism in Patient With Malignancy. , 2023, , .		0
1612	MARKERS FOR THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH DISSEMINATED COLON CARCINOMA. Russian Journal of Oncology, 2012, 17, 48-53.	0.1	0
1613	Colorectal cancer screening at age 45 years in Israel: Costâ€effectiveness and global implications. Cancer, 2024, 130, 901-912.	4.1	0
1614	Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced- retinopathy mouse model. Chinese Medical Journal, 2013, 126, 345-352.	2.3	0
1615	Cardiovascular disease and lung cancer. Frontiers in Oncology, 0, 14, .	2.8	0

#	Article	IF	CITATIONS
1616	Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers, 2024, 16, 890.	3.7	0
1617	Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics Journal, 2024, 24, .	2.0	0